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Studying the Role of Lipocalin-2 in the Pathophysiology of Multiple Sclerosis – Looking beyond the brain 
ABSTRACT 
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system 
(CNS), characterized by the presence of demyelination plaques, inflammation and gliosis that 
consequently lead to axonal damage. The sequence of events that leads to demyelination remains 
unclear and the pathophysiological mechanisms are diverse. Also, although this is a disease of the 
CNS, there is no doubt that, in terms of peripheral organs, the thymus, as the organ of T cell 
differentiation and maturation, plays an important role in the pathophysiology of the disease.  
Recently, the levels of lipocalin 2 (LCN2), an acute phase protein that is part of the defense system 
against bacteria, by binding to iron-loaded siderophores, were found to be increased in cerebrospinal 
fluid (CSF) and serum of MS patients, when compared to control subjects. Similarly, using the MS 
animal model of experimental autoimmune encephalomyelitis (EAE), LCN2 was detected in brain 
parenchyma astrocytes, in regions typically affected in MS patients. This expression by astrocytes, 
together with an increased LCN2 level in the CSF, occurs during the active phases of the disease, which 
could point towards a role for LCN2 secreted by astrocytes in the mediation of inflammatory responses 
in the EAE model. Altogether, these findings support LCN2 as a valuable molecule for the 
diagnostic/monitoring of MS and suggest its potential involvement as a disease modulator. Of 
relevance, the exact role of LCN2 in the pathophysiology of the disease remains largely unknown and 
contradictory data exists on its potential protective or deleterious effect. Therefore, we sought to 
investigate the role of LCN2 in the onset and progression of the disease. Herein, we tackled the 
disease, by evaluating the role of LCN2, not only in the perspective of the CNS, but also on the 
perspective of peripheral organs such as the thymus. 
First we intended to perform a characterization of the thymus regarding thymocyte populations and 
histological morphology, in wild-type (WT) animals induced with EAE, in the onset and chronic phases of 
disease. Next, to further understand the role of LCN2 in MS pathology, we induced EAE both in LCN2-
null mice and in WT littermates. Non-induced EAE animals were used as controls. 
The thymus of EAE animals was atrophied, as assessed by its weight, normalized for total body weight, 
and by the number of total cells. Also, we found a decrease in total cell number of all thymocyte 
populations, during the onset and chronic phases of EAE. In relative terms, the percentage of double 
positive cells was decreased, and the percentages of the cluster of differentiation (CD)4 and CD8 single 
positive cells were increased, during the onset phase. At the chronic phase, the proportions between 
the different populations were restored.  
LCN2-null mice induced with EAE did not present major alterations in terms of the clinical score, when 
compared with WT littermates also induced with EAE. Likewise, their thymic alterations were similar to 
the ones observed in WT EAE animals. Of relevance, as for the inflammatory profile in the cerebellum, 
LCN2-null mice presented less inflammation, as assessed by decreased expression levels of pro-
inflammatory cytokines interferon (Ifn)-gamma, interleukin (Il)12a and Il17a. Also of interest, the 
cerebellum of LCN2-null mice presented a decrease in the percentage of lesioned areas. Finally, EAE 
animals, from both genotypes, presented an increase in the area positive for glial fibrillary acidic protein 
(GFAP), in the white matter of the cerebellum, in both the onset and chronic phases of disease. On the 
contrary, the expression levels of Gfap in the cerebellum were only increased at the onset phase of 
disease.  
KEYWORDS: MULTIPLE SCLEROSIS, LIPOCALIN-2, NEUROINFLAMMATION, ASTROCYTES, THYMUS, EXPERIMENTAL 
AUTOIMMUNE ENCEPHALOMYELITIS 
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O papel da lipocalin-2 na patofisiologia da Esclerose Múltipla – Um olhar para além do cérebro 
RESUMO 
A Esclerose Múltipla (EM) é uma doença autoimune desmielinizante do sistema nervosa central (SNC), 
caracterizada pela presença de placas de desmielinização, inflamação e gliose, que tem como 
consequência dano axonal. A sequência de eventos que induzem desmielinização permanecem 
desconhecidos, e os mecanismos patofisiológicos são diversos. Embora esta seja uma doença do SNC, 
não há dúvidas que, em termos de órgãos periféricos, o timo, sendo o órgão de maturação e 
diferenciação das células T, desempenha um papel importante na patofisiologia da doença. 
Recentemente, os níveis de lipocalin-2 (LCN2), uma proteína de fase aguda que participa no sistema 
de defesa contra infeções bacterianas, através da ligação a sideróforos, foram encontrados como 
estando elevados no líquido cefalorraquidiano (LCR) e no soro de doentes com EM, comparativamente 
aos controlos. Da mesma maneira, usando o modelo animal de EM de encefalomielite autoimune 
experimental (EAE), a LCN2 foi detetada em astrócitos do parênquima, em regiões tipicamente 
afetadas em doentes com EM. Esta expressão pelos astrócitos, associada a um aumento de LCN2 no 
LCR, ocorreu durante as fases ativas da doença, o que aponta para um papel da LCN2 secretada pelos 
astrócitos na mediação da response inflamatória no modelo de EAE. No seu conjunto, estas evidências 
suportam o papel da LCN2 como uma molécula importante no diagnóstico e/ou monitorização da EM, 
e sugere o seu possível envolvimento como moduladora da doença. É relevante dizer que o papel exato 
da LCN2 na patofisiologia da doença permanece desconhecido, e existem dados contraditórios no que 
diz respeito ao seu potencial efeito protetor ou deletério. Por isso, nós procurámos perceber o papel da 
LCN2 no onset e na progressão da doença. Assim, nós investigámos o papel da LCN2 na doença, não 
só na perspetiva do SNC, mas também dos órgãos periféricos, nomeadamente do timo. 
Primeiro pretendemos caracterizar o timo em relação às populações de timócitos e morfologia 
histológica, em animais wild-type (WT) induzidos com EAE, no onset e na fase crónica da doença. De 
seguida, para melhor entender o papel da LCN2 na patologia da EM, induzimos EAE em animais LCN2-
null e em WT da mesma ninhada. Para além disso, usámos animais não induzidos como controlos. 
Nós observámos que o timo dos animais induzidos com EAE estava atrofiado, com base no seu peso, 
após normalização para o peso total do animal, e no número total de células. Para além disso, 
encontrámos uma diminuição no número total de células de todas as principais populações de 
timócitos, durante o onset e fase crónica da doença. No que diz respeito à percentagem de cada uma 
das populações de timócitos, durante o onset da doença, a percentagem de células duplas positivas 
encontrava-se diminuída, enquanto as percentagens das populações CD4+CD8- e CD4-CD8+ se 
encontrava aumentada. Na fase crónica da doença, as proporções entre as diferentes populações 
foram reestabelecidas. 
Os animais LCN2-null induzidos com EAE não apresentaram grandes alterações em termos de score 
clínico, quando comparados com os animais WT da mesma ninhada também induzidos com EAE. Para 
além disso, as alterações observadas no timo foram semelhantes às encontradas nos animais WT EAE. 
De relevância, no que diz respeito ao perfil inflamatório no cerebelo, os animais LCN2-null 
apresentaram menos inflamação, o que é suportado por níveis diminuídos dos níveis de expressão das 
citoquinas pró-inflamatórias interferão-gama, e interleucinas 12 e 17. É importante também referir que 
os cerebelos de animais LCN2-null apresentaram uma diminuição na percentagem de áreas com 
lesões. Os animais EAE, de ambos os genótipos, apresentaram um aumento na área positiva para 
GFAP, na substância branca do cerebelo, no onset e na fase crónica da doença. Pelo contrário, os 
níveis de expressão de Gfap no cerebelo só foram encontrados elevados no onset da doença. 
PALAVRAS-CHAVE: ESCLEROSE MÚLTIPLA, LIPOCALINA-2, NEUROINFLAMAÇÃO, ASTRÓCITOS, TIMO, ENCEFALOMIELITE 
AUTOIMUNE EXPERIMENTAL  
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1. INTRODUCTION 
1.1 Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic immune mediated demyelinating disease of the central nervous 
system (CNS) (Lassmann & van Horssen, 2011; Noseworthy et al., 2000). In developed countries it is 
the second cause of neurological disability in young adults, with high burden for the patient, the family 
and the resources of the health system (Borreani et al., 2014). MS is a complex disease in which there 
is a strong immune response against the myelin sheath of CNS axons, but its underlying mechanisms 
are only partially understood.  Most patients initially present with a clinically isolated syndrome (CIS) in 
early adulthood. These CIS patients present an acute episode, which typically affects one brain region, 
being the clinical symptoms variable depending on the involvement of motor, sensory, visual or 
autonomic systems. (Compston & Coles, 2008). Some CIS patients will evolve to definite MS disease, 
while others won’t. Nowadays, the diagnosis of definite MS is based on recognized clinical criteria, with 
the support of magnetic resonance imaging (MRI) data and cerebrospinal fluid (CSF) analysis 
(Noseworthy et al., 2000), and can only be done when there is dissemination of neurologic dysfunction 
in space and time (Compston & Coles, 2008; Noseworthy et al., 2000; Polman et al., 2011), and after 
differential diagnosis have been excluded (Polman et al., 2011). Concerning the MRI findings, the 
presence of multifocal demyelinating lesions at different timepoints involving preferentially the 
periventricular white matter, the brain stem, the cerebellum and the spinal cord are indicative of MS 
(Noseworthy et al., 2000). Besides this, the presence of oligoclonal bands or increased concentration of 
immunoglobulin (Ig)G in the patients’ CSF are widely used to support MS diagnosis, but are not MS-
specific (Fossey et al., 2007; Noseworthy et al., 2000). 
Patients with definite MS can develop different profiles of the disease. Taking in consideration the 
different profiles of the disease, MS can be classified as relapse-remitting (RR)-MS, primary progressive 
(PP)-MS or secondary progressive (SP)-MS. RR-MS represents about 80-85% of MS cases (Sospedra & 
Martin, 2005) and is characterized by transient symptoms (relapse) that in most of the times improve 
within weeks (remission). However, the ability to fully recover from relapse episodes diminishes with 
time, and irreversible damage accumulates in the CNS, giving rise to SP-MS. The remaining 15-20% of 
patients has PP-MS, and does not show this relapse-remitting pattern; rather, their symptoms become 
gradually worst along the course of the disease. The RR-MS presents a female to male ratio of 2:1, 
while in the PP-MS the incidence is similar between both genders (Noseworthy et al., 2000). 
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Noticeably, some CIS patients never progress to definite MS. But in those patients that do evolve, an 
early treatment might reduce disease severity. Taking this into account, it is crucial to find new 
therapeutics to reduce not only the strong pro-inflammatory reaction, but also the relapse rate and, 
consequently, delay irreversible damage (Comi et al., 2000). Another challenge regarding MS has been 
to identify the CIS patients that present a high risk of having future episodes, which would confirm the 
diagnosis of definite MS (Brettschneider et al., 2010). This identification could be done based on 
disease biomarkers, measured in the patients’ blood or CSF. However, the etiology and the 
pathogenesis of MS are poorly understood, which makes it harder to find appropriate biomarkers for 
disease initiation and progression. (Lassmann & van Horssen, 2011). 
1.2 Etiology of MS disease 
1.2.1 Environmental and genetic factors 
Regarding the etiology of MS, both environmental factors, such as infectious agents and lifestyle, and 
genetic factors have been proposed to induce or contribute to disease appearance (Compston & Coles, 
2008; Sospedra & Martin, 2005). Among the environmental factors, the influence of viral infections is 
being largely addressed but until now nothing was proved. Regarding viral infections, it was shown that 
human herpesvirus-6 or Epstein-Barr viruses, may trigger a cascade of inflammatory events that lead to 
MS. In addition, because a higher proportion of women suffer from MS it was suggested that changes in 
hormone levels may influence disease initiation (Sospedra & Martin, 2005). Moreover, variations in 
sunlight exposure were also strongly associated with increased MS risk (Ebers, 2008), mostly due to 
changes in melatonin production. Specifically, it was shown that an excess of melatonin induced by 
decreased sunlight exposure enhances the Th1 response, boosting the inflammatory response 
(Sospedra & Martin, 2005). Finally, in the field of the genetic factors, genome-wide association studies 
have identified the allele for human leukocyte antigen (HLA)-DRB1*15:01 as the haplotype that 
represents the highest risk factor for MS (Nylander & Hafler, 2012; Sawcer et al., 2014). This haplotype 
explains between 14-50% of the genetic risk for MS (Hafler et al., 2005; Sawcer et al., 2014). Other 
susceptibility in non-HLA loci were also identified as being associated with MS, being most of them 
involved in the immunological response, especially in T cell immunity, like the interleukin (IL)2 receptor 
α gene (Il2Rα) and the IL7 receptor α (Il7Rα) gene (Berge et al., 2013; Hafler et al., 2007). 
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1.2.2 Onset mechanism 
MS pathogenesis is fostered by a dysregulated autoimmune response. Initially, naïve myelin-specific T 
cells are primed in the lymph nodes by antigen presenting cells (APCs) that present myelin cross-
reactive epitopes (Nakahara et al., 2010). During this process, an unknown mechanism triggers the 
activation of autoreactive T cells, which start to show cross-reactivity to self-antigens, such as proteins 
found in the myelin sheath, namely myelin basic protein (MBP), myelin oligodendrocyte protein (MOG) 
and proteolipid protein (PLP) (Steinman, 2001) (phase 1, Figure 1). After the initial priming of T cells, 
they migrate to the CNS and cross the endothelium, breaching the blood-brain barrier (BBB) (phases 2-
4, Figure 1). The crossing is facilitated by the expression of the integrin very late antigen (VLA)-4 by 
activated T cells, which will interact with the vascular cell adhesion protein (VCAM) expressed by 
inflamed endothelial cells (Reboldi et al., 2009; Steinman, 2001). Likewise, activated T cells express 
members of the immunoglobulin superfamily, such as cluster of differentiation (CD)4 and CD8, which 
will interact with endothelial cells via major histocompatibility complex (MHC) class II and class I 
molecules, respectively. Moreover, the transendothelial migration of T cells is facilitated by 
metalloproteinases (MMP)2 and 9, which play a role in the degradation of the extracellular matrix, and 
are detectable in the CSF of MS patients (Steinman, 2001). Besides entering through the BBB, 
activated autoimmune T cells are also able to enter the CNS through the choroid plexus (CP), which 
forms the blood-CSF barrier. (Reboldi et al., 2009) Once the barriers of the brain have been breached, 
inflammatory cells spread into the white matter of the CNS, and are re-activated by myelin epitopes 
(Nakahara et al., 2010) (phase 5, Figure 1). The re-activated T cells in particular will produce cytokines 
and chemokines, which will promote the recruitment of other immune cells, like B cells (Miller, 2012), 
monocytes, and mast cells (Sospedra & Martin, 2005), from the periphery, and activate resident cells, 
namely microglia and astrocytes, inducing the production of nitric oxide (NO) and osteopontin 
(Sospedra & Martin, 2005; Steinman, 2001). Increased levels of NO are a major contributor for the 
death of oligodendrocytes and osteopontin induces the production of T helper (Th)1 cytokines, namely 
interferon (IFN)-Ȗ and interleukin (IL)-12, and down-regulates Th2 cytokine production, contributing to 
an exacerbation of MS. The end result of this combined response by innate and adaptive immune cells, 
and respective inflammatory mediators, is the formation of an inflammatory lesion (phase 6, Figure 1), 
characterized by demyelinated axons, apoptotic oligodendrocytes, macrophages loaded with 
phagocytized myelin lipids, and activation and proliferation of astrocytes (Sospedra & Martin, 2005). It 
is believed that, upon lesion formation, brain cells are recruited to the injury site to promote 
regeneration of the tissue. In particular, oligodendrocyte precursor cells (OPCs) are recruited to the 
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lesion sites and differentiate into myelinating oligodendrocytes that are able to remyelinate denuded 
internode areas. In these areas the nerve conduction velocity is slower than before, because the myelin 
sheath produced is less thick than the original one, which also leads to the redistribution of sodium 
channels as a compensation measure (Sospedra & Martin, 2005). 
 
    
Figure 1 - Proposed pathogenic pathway involved in MS. 
 
Another proposed theory for the pathogenesis of MS is the oligodendrogliopathy hypothesis. According 
to this hypothesis, the inflammation is not the cause of demyelination, but instead is the result of 
oligodendroglial apoptosis, myelin degeneration and impaired myelin regeneration. The lesions result 
from apoptosis of oligodendrocytes, which induce myelin degeneration and the recruitment of 
macrophages to eliminate the myelin debris. Consequently, immune reactions involving T and B cells 
occur along with a slower and poorly effective oligodendroglial regeneration and remyelination 
(Nakahara et al., 2010). However, considering that most of the susceptible loci identified for MS are 
located in genes involved in the immunological response (Berge et al., 2013), this favours the first 
theory, i.e. an initial immune dysregulation followed by secondary degenerative processes (Slavin et al., 
2010).  Nevertheless, and considering that the clinical, genetic, MRI and pathological data is 
heterogeneous in MS, it is highly possible that more than one pathogenetic mechanism contributes to 
disease establishment (Noseworthy et al., 2000), which rises the necessity for the development of 
therapies that not only modulate the immune response, but can also act on other disease targets, like 
oligodendrocytes and axons (Lucchinetti et al., 2005). 
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1.3 MS symptoms 
MS patients usually present the first symptoms of disease between the ages of 20 and 40. Disease 
activity results in reversible but also in irreversible sequelae. Irreversible sequelae ultimately lead to 
progressive impairment and disability in the majority of patients. Common symptoms among MS 
patients include sensory problems, such as numbness or tingling, weakness, difficulties walking, double 
vision and poor coordination. However, no two patients have exactly the same symptoms. With disease 
progression patients start to develop increased disability, showing problems in bladder and bowel 
control, cognitive performance and sexual performance. They may also present fatigue, even after a 
good night’s sleep, and walking problems. Ultimately, MS patients need wheelchair and can become 
bedridden (Joy & Johnston Jr., 2001). 
The first symptoms presented by MS patients are widely believed to result from the exacerbated 
inflammatory process, which is associated with reduction of the nerve conduction velocity, and, on the 
other hand, the regression of symptoms correlates with the resolution of the inflammatory lesion and 
partial remyelination. As already mentioned, the axonal injury resultant from repeated episodes can 
become irreversible. In this case there is the formation of a glial scar and also there is an exhaustion of 
the OPCs pool, leading to progressive loss of neurological function, and to the formation of 
demyelinating plaques  (Noseworthy et al., 2000). Altogether, the presence of focal demyelination, 
inflammation, glial scar formation and varying axonal damage are considered the hallmarks of MS 
disease (Lucchinetti et al., 2005). 
Over the last years, the use of animal models has provided important insights into MS pathophysiology 
of MS and possible therapeutic targets. In the next section we will present the main characteristics of 
the animal models used to study MS, with special attention given to the experimental autoimmune 
encephalomyelitis (EAE) model, which is the most common animal model for studying MS.   
1.4 MS animal models – Experimental autoimmune encephalomyelitis 
Human studies have some limitations, such as limited access to human tissue, especially from living 
patients, the fact that the experimental design of clinical trials cannot be easily modified, and the fact 
that studies of disease mechanisms are difficult to perform in humans (Denic et al., 2011). For that 
reason, the importance of animal studies relies on the fact that they provide flexible, potent and rapid 
platforms for MS research (Ransohoff, 2012). As already mentioned, the etiology and pathogenesis of 
MS are still unclear, which makes it difficult to find one animal model that accurately represents all 
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aspects of this disease (Denic et al., 2011). Instead, there are currently three main models that are 
used to study different pathological characteristics of MS: (1) viral models of inflammatory 
demyelination; (2) demyelination induced by toxic agents; (3) inducible models of EAE (Batoulis et al., 
2011; Procaccini et al., 2015). Besides these three models, there are T-cell receptors (TCR) transgenic 
mice models that spontaneously develop EAE (Croxford et al., 2011; Wekerle & Kurschus, 2006).  
The Theiler’s murine encephalomyelitis virus (TMEV) is the best characterized model of virus-induced 
demyelination. It is used to study how viral infections are able to induce CNS autoimmunity (Batoulis et 
al., 2011). In this model, the animals are inoculated with a virus, which will induce acute inflammation 
in the CNS, and ultimately lead to demyelination and axonal damage in the CNS (Batoulis et al., 2011; 
Denic et al., 2011). Susceptible mice always develop a chronic-progressive form of disease (Batoulis et 
al., 2011). One disadvantage of this model is the induction of a special inflammatory environment, by 
the virus, which is unlikely to reflect what happens in typical MS lesions (Wekerle & Linington, 2006). 
Toxin-induced models of demyelination include the cuprizone and the lysolecithin models. Cuprizone is 
a copper chelator, which causes demyelination, with minor inflammation or axonal damage, 
predominantly in the cerebellar cortex and peduncle, when fed to the animals. This is a good model to 
study the main characteristics of focal demyelination and also remyelination (Batoulis et al., 2011; 
Denic et al., 2011; Fossey et al., 2007), since spontaneous remyelination is observed after withdrawal 
of cuprizone  (Mix et al., 2010). Lysolecithin is used to induce focal demyelination, after injection 
directly in the white matter, which allows the control of the lesion size, nature and anatomical location 
(Woodruff & Franklin, 1999). 
The EAE animal model has been used to study MS since the initial observation of paralysis, 
accompanied by perivascular infiltration and demyelination, in the pons and cerebellum of monkeys 
that were given repeated intramuscular injections of normal rabbit brain extracts (Rivers et al., 1933). 
Since then, a variety of mammals have been induced with EAE, from mice and rats, to goats and sheep 
(Denic et al., 2011). This is a model of antigen-specific autoimmunity against myelin, mediated by 
CD4+ T cells, which results in inflammatory demyelination of brain and spinal cord of induced animals 
(Dal Canto et al., 1995). Due to the clinical, immunopathological and histopathological similarities with 
MS, the EAE model is the most commonly used to study this human disease (Swanborg, 1995). This 
model has numerous applications, especially in the study of mechanisms involved in autoimmune-
mediated inflammation, demyelination, axonal damage, immune cell migration across the BBB and 
regulatory mechanisms that can supress autoimmunity in the CNS (Stromnes & Goverman, 2006).   
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There is not one single model of EAE, but instead, the different combinations of animal species and 
strains, type of antigen used for immunization and the type of adjuvant employed give rise to different 
models, that differ from each other in the type of disease course (chronic vs. monophasic vs. relapse-
remitting) (Swanborg, 1995), lesion location and involvement of B cell produced antibodies vs. T cell 
responses, sustaining the notion that antigens and immunogenetic background contribute to disease 
phenotype (Sospedra & Martin, 2005). As an example, Slavin and co-workers (1998) have shown that 
immunization of different strains of mice with the same peptide leads to different outcomes – after EAE 
induction with MOG35-55, nonobese diabetic (NOD/Lt) mice presented a relapse-remitting course of 
disease, while C57BL/6 mice showed a chronic non-remitting disease, and BALB/c mice were not 
susceptible to disease induction (Slavin et al., 1998).  
EAE can be induced actively, when the animals are immunized with CNS antigens, or passively, if 
autoreactive CD4+ T cells obtained from immunized animals are transferred into naïve animals 
(Batoulis et al., 2011; Dal Canto et al., 1995). Some of the CNS antigens used to induce EAE are 
purified MBP or PLP; whole spinal cord homogenates; or specific peptides, which correspond to the 
encephalitogenic portion of a protein for a given strain (Dal Canto et al., 1995), such as the MOG35-55 
peptide. Unlike MBP and PLP, which together represent about 80-90% of CNS myelin proteins, MOG 
only accounts for 0.01-0.05% of these proteins, but its location at the outermost lamellae of the 
oligodendrocyte membrane makes it easily accessible to antibodies, hence its importance as a cellular 
and humoral target in MS and EAE (Slavin et al., 1998; Sospedra & Martin, 2005).  Since the MOG35-55-
induced mice model, specifically in C57BL/6 mice, will be used in the context of the present thesis we 
will further characterize it in the next paragraph. 
As previously shown, C57BL/6 mice induced with MOG35-55 present a chronic course of disease (Slavin 
et al., 1998; Sospedra & Martin, 2005), characterized by ascending paralysis resultant from the 
preferential attack to the spinal cord (Batoulis et al., 2011). The disease is characterized in the 
beginning by a limp tail, which progresses to hind and forelimbs paralysis (Stromnes & Goverman, 
2006). Also multifocal and confluent areas of mononuclear inflammatory infiltrates and perivascular 
inflammatory cuffing in the cerebellum and hindbrain white matter are observed. The chronic disease 
course makes this a good model to study SP-MS (Constantinescu et al., 2011). The MOG35-55-induced 
C57BL/6 model is particularly important in MS studies due to the increased availability of gene-
modified strains on this background (Kuerten et al., 2007; Ransohoff, 2012). One disadvantage of the 
EAE model arises from the use of Freund’s complete adjuvant (CFA) and pertussis toxin (PTX) for active 
disease induction. CFA contains bacterial components that are able to activate the innate immune 
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system, via pattern recognition receptors (Constantinescu et al., 2011), and, consequently, 
misrepresent the animals’ general immune reactivity and confound the findings related with regulatory 
mechanisms (Wekerle & Kurschus, 2006). In the case of PTX, it will contribute to BBB permeabilization 
and facilitate autoantigen recognition in the CNS, by activating tissue-resident APCs (Kuerten & 
Lehmann, 2011). When it comes to all EAE models, other limitations can be pointed out, namely, the 
early detection of clinical signs in EAE, as compared with MS, which allows an early therapeutic 
intervention in the case of the animal model that cannot be translated into the human disease. 
Moreover, several therapies tested in EAE have proven ineffective or even harmful in human patients. 
These differences might be explained by the lower disruption of the BBB in MS patients, as compared 
with EAE-induced animals, which could prevent the therapeutic molecules from reaching their target in 
the CNS (Mix et al., 2010; Procaccini et al., 2015). Additionally, EAE is induced on highly inbred strains 
that are kept in a pathogen-free environment, with controlled temperature, light and humidity 
conditions, which is not representative of the various environmental and genetic factors that contribute 
to MS susceptibility (Handel et al., 2011). Besides, if we take into account that in the EAE model a 
CD4+ T cell response is induced, it becomes difficult to study the role of CD8+ T cells, which have been 
shown to be key players in MS pathogenesis (Procaccini et al., 2015; Ransohoff, 2012). Another 
difference that has been pointed out is the preferential involvement of the spinal cord in the EAE model, 
unlike the human disease, in which the cerebral and cerebellar cortex are more affected (Brown & 
Sawchenko, 2007; Procaccini et al., 2015; Ransohoff, 2012). Nevertheless, other brain structures have 
been proven to also be involved in the EAE model, namely the cerebellum and optic tract (Brown & 
Sawchenko, 2007). 
Briefly, both in MS and in MS animal models there are four key pathological features: inflammation, 
demyelination, axonal loss or damage and gliosis (Constantinescu et al., 2011; Lucchinetti et al., 
2005). So it is not surprising that glial cells also play a key role in MS pathophysiology. It was already 
mentioned that after T cell re-activation, in the CNS, there is the production of cytokines and 
chemokines which will activate microglial cells and astrocytes, leading to oligodendrocyte damage 
(Miller, 2012; Sospedra & Martin, 2005; Steinman, 2001). In the next section we will discuss the main 
characteristics of CNS glial cells and their participation in MS/EAE pathophysiology. 
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1.5 The role of glial cells in EAE 
There are 3 types of glial cells in the mature CNS: astrocytes, oligodendrocytes and microglial cells 
(Purves et al., 2001), and all of them have been reported as being involved in MS pathogenesis. 
1.5.1 Oligodendrocytes  
Oligodendrocytes are responsible for producing myelin that wraps around some, but not all, neuronal 
axons. The oligodendrocyte-myelin-axon unit represent a unique structure, with specialized functions, 
within the CNS. Myelin contributes not only to increase the cross-sectional diameter of axons, 
increasing the velocity of action potential conduction, through saltatory conduction (Frohman et al., 
2006; Purves et al., 2001), but also for the axonal stability, and normal neuronal functioning, by 
inducing sodium channel clustering, via oligodendrocyte-derived soluble factors, even in the absence of 
direct axon-glial contact (Chandran et al., 2008; Kuerten & Lehmann, 2011). During the course of MS 
and EAE, oligodendrocyte death occurs, mediated by endogenous factors, such as the activation of cell 
death by caspase-11 and caspase-3, via specific pathways (Hisahara et al., 2001), or by the release of 
cytotoxic cytokines by activated microglia and astrocytes, namely IFN-Ȗ (Vartanian et al., 1995). 
New oligodendrocytes that participate in remyelination could arise either from surviving 
oligodendrocytes or OPCs at the lesion sites, or from OPCs that migrate to the lesion (Reynolds et al., 
2002). Taking into account that mature oligodendrocytes are post-mitotic cells, it is very unlikely that 
they could originate new functional oligodendrocytes. OPCs have been identified in chronic lesions, 
although in a relatively quiescent state (Chari & Blakemore, 2002), and have also been shown to 
proliferate after acute demyelination (Reynolds et al., 2002), hence they are the most probable 
candidates involved in remyelination. This idea is supported by studies in which, after labelling OPCs in 
normal white matter and inducing demyelination, it was possible to locate these cells as remyelinating 
oligodendrocytes. Also, the transplantation of OPCs, isolated from the adult CNS, was found to be able 
to remyelinate areas of demyelination (Franklin, 2002). Consequently to an acute demyelination 
episode, induced by chemical or immunological mechanisms, neural/glial antigen 2 (NG2)+ OPCs 
become reactive, proliferate, and migrate to the lesion sites (Reynolds et al., 2002). At the lesion sites, 
OPCs have to be able to differentiate into functional myelinating oligodendrocytes (Chari & Blakemore, 
2002). 
Different theories try to explain why remyelination fails in MS. One of the most popular theories claims 
that failure in remyelination arises from exhaustion of the pool of OPCs, induced by repeated episodes 
of inflammation and demyelination (Reynolds et al., 2002). It could also be that the local OPCs present 
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are not able to further differentiate into myelinating oligodendrocytes, due to the lack of differentiation 
signals or to the presence of inhibitory signals (Back et al., 2005; Franklin, 2002), such as hyaluronan 
(Williams et al., 2007).  
In addition, studies using organotypic cultures of cerebellum, challenged with lipopolysaccharide (LPS), 
have shown microglia activation, characterized by morphological changes from ramified to amoeboid 
shaped cells, the production of pro-inflammatory cytokines, like IL-1ȕ, IL-6 and tumor necrosis factor 
(TNF)-α, and the induction of oxidative stress, via production of reactive oxygen species (ROS) and 
inducible nitric oxide synthase (iNOS) (di Penta et al., 2013). This microglia activation was associated 
with oligodendrocyte death, and myelin and axonal damage (di Penta et al., 2013). 
1.5.2 Microglia  
Microglial cells are considered to be the macrophages of the brain, due to their myeloid origin, ability to 
circulate and migrate within different regions of the brain, and to phagocyte, process and present 
antigens. In this sense, microglial cells are the CNS-resident immune cells, functioning as the first line 
of defense against immune and inflammatory stimuli (Lee et al., 2007). Under physiological conditions, 
resting microglia play a crucial role in the immune surveillance of the brain, interacting with the other 
brain cells and actively monitoring and remodelling impaired synapses. Subsequently to CNS damage, 
the number of microglial cells increases dramatically at the lesioned site, due to proliferation of resident 
microglia and migration of monocytes, from circulation (Purves et al., 2001). These cells share many 
properties with tissue macrophages, namely they are scavenger cells that remove cellular debris from 
injury sites (Purves et al., 2001). This phagocytic removal of apoptotic cellular material, without 
induction of inflammation, is one of the main beneficial roles of microglia. However, microglial cells are 
unable to efficiently remove myelin debris when Wallerian degeneration is associated with acute injury, 
preventing axonal regeneration. Principally after activation, these cells are able to secrete important pro- 
or anti-inflammatory mediators that act as paracrine mediators of neural cell migration and survival, but 
may also promote the autocrine polarization of microglia into different states of activation, the M1 and 
M2 microglia. In the first case microglial activation is more harmful, and in the second is more 
protective. Furthermore, microglial cells are involved in CNS repair, by producing cytokines and 
chemokines, but can also induce oligodendrocyte death through the production of cytotoxic molecules. 
Another beneficial function that has been attributed to microglia is the ability to recruit stem cells and 
induce neurogenesis (Napoli & Neumann, 2010). In response to an inflammatory stimuli, microglia 
upregulate CD45, CD86, CD80, CD40 and MHC-class II, enhancing their ability to function as APC 
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(Minagar et al., 2002; Murphy et al., 2010). Moreover, persistent activation of microglia contributes to 
increase the permeability of the BBB, and promotes the infiltration of peripheral macrophages (Miller, 
2012). It was already referred that MMP2 and MMP9 are important in MS pathogenesis, more 
specifically, for facilitating T cell transendothelial migration (Steinman, 2001). In the CNS, these two 
MMPs are secreted by microglia and astrocytes as active forms (Nakanishi, 2003). Thus, microglia can 
exert both beneficial and detrimental functions during disease development, depending on the stage 
and context of a given lesion (Correale, 2014).  
1.5.3 Astrocytes 
Astrocytic involvement in MS has long been recognized. A few years before Charcot described a 
disease, which he called “Sclérose en plaques”, in 1868, Rindfleisch had already described the 
presence of multinucleated cells with processes in a CNS pathology named “grey degeneration”. These 
cells were later identified as astrocytes (Williams et al., 2007). In physiological conditions, astrocytes 
play an essential role in maintaining survival of neurons and other glial cells (Miller, 2012), by providing 
structural support to neurons  (Nair et al., 2008), maintaining the extracellular ionic environment and 
pH and secreting metabolic substrates for neurons (Sofroniew, 2005). They are also able to actively 
alter the synaptic transmission by clearing and releasing extracellular glutamate from/to the synaptic 
cleft (Nair et al., 2008; Sofroniew, 2005). In addition, perivascular astrocytes are tightly associated with 
the basal lamina of blood vessels, contributing for the maintenance of the BBB (Brambilla et al., 2014). 
Following a CNS insult, like injury, ischemia and neurodegeneration, astrocytes become reactive and 
suffer morphological changes, such as cytoplasm enlargement, increased size and ramification of 
processes (Lee et al., 2009), upregulation of glial fibrillary acidic protein (GFAP) and vimentin, and re-
expression of nestin (Williams et al., 2007). Astrocytes, along with microglial cells, play a dual role in 
protection and injury in MS (Minagar et al., 2002). 
In situations of CNS insult, astrocytes upregulate the expression of glutamate transporters and 
glutamine synthetase, preventing the extracellular accumulation of glutamate, and consequently its 
excitotoxic effects on neurons and oligodendrocytes (Nair et al., 2008; Sofroniew, 2005). Also, 
astrocytes produce chemokines, that are able to recruit OPCs to demyelination sites (Williams et al., 
2007), and anti-inflammatory cytokines, such as IL-10, IL-4, IL-5, IL-27 and transforming growth factor 
(TGF)-ȕ (Nair et al., 2008). The formation of a reactive scar by astrocytes, on one hand, helps to 
surround and separate the damaged tissue from normal white matter, but on the other hand, presents 
as a major obstacle for axon regeneration (Sofroniew, 2005). The gliotic scar could also result from a 
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failed attempt of remyelination (Franklin, 2002). In addition, astrocytes further contribute for the 
permeabilization of the BBB by secreting IL-6, TNF-α and IL-1β, which will act specifically on endothelial 
cells and tight junctions (Nair et al., 2008). As mentioned previously, astrocytes can express MMPs 
(Nakanishi, 2003), but they are also able to express tissue inhibitors of metallopeptidases (TIMP)-1, that 
regulate negatively the activity of MMPs (Nair et al., 2008; Williams et al., 2007). 
Reactive GFAP+ astrocytes were found in the spinal cords of Lewis rats induced with EAE, even before 
the appearance of disease clinical symptoms (Smith et al., 1983). Also, in a mice model of EAE with a 
chronic relapsing disease course [model characterized by both relapsing-remitting episodes, with 
inflammatory-mediated demyelination, and progressive disease, with axonal and neuronal loss 
(Ramaglia et al., 2015)], astrocytic activation was found at lesion sites, and Gfap expression levels were 
found to fluctuate according to the symptomatic stage of disease (Kothavale et al., 1995). Of relevance, 
when a drug that targets glial activation was used, it seems that there was a reduction in both clinical 
and pathological severities of EAE, namely there was a partial rescue of oligodendrocytes from cell 
death (Guo et al., 2007). Previously, GFAP-null mice induced with EAE presented a more severe clinical 
course, supporting the importance of GFAP in structural stabilization of the white matter (Liedtke et al., 
1998). Altogether, these findings suggest that an excessive glial response is deleterious for EAE 
recovery, but a defective glial response is also unable to delimitate lesion sites, and protect the healthy 
surrounding tissue from secondary degeneration. 
Previous in vitro and in vivo studies from our laboratory have shown the production by astrocytes of an 
acute-phase protein, lipocalin-2 (LCN2), in response to different inflammatory stimuli, namely in the 
EAE context. We will further assess this subject and describe the possible involvement of LCN2 in MS 
and EAE pathogenesis. 
1.6 Lipocalin-2  
Lipocalin-2 (LCN2), also known as neutrophil gelatinase-associated lipocalin (NGAL) or 24p3, was first 
identified by Kjeldsen and colleagues (1993) as a protein present in neutrophil granules, partly 
covalently associated with human neutrophil gelatinase (Kjeldsen et al., 1993, 1994). LCN2 is a 
member of the lipocalin family, whose members are characterized by a compact tertiary structure, with 
a central hydrophobic core that allows the binding to small lipophilic substances (e.g. retinol), along 
with an ability to bind specific cell-surface receptors and to covalently associate with other proteins, 
leading to the formation of molecular complexes (Flower, 1996; Kjeldsen et al., 1994). 
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Initial reports described LCN2 as an acute phase protein in mice, involved in acute responses to various 
inflammatory or stressful stimuli (Q. Liu & Nilsen-Hamilton, 1995; Marques et al., 2008).  
The particular production of LCN2 upon bacterial infection is suggested to occur as part of the innate 
immune response (Flo et al., 2004). Invading pathogens, when confronted with the low levels of iron 
present in the host, and in order to proliferate, secrete siderophores, small binding molecules that have 
higher-affinity to iron than the endogenous host iron-trafficking proteins. To cope with this, and at the 
site of infection, neutrophils release LCN2, which will then bind specifically to the bacterial ferric 
siderophores, preventing iron from being transported into the bacteria (Flo et al., 2004; Goetz et al., 
2002). The importance of this mechanism is demonstrated by the fact that LCN2-null mice have 
increased susceptibility to bacterial infection (Flo et al., 2004). 
More recently, LCN2 was also found to interact with endogenous iron (Yang et al., 2002) using an 
endogenous mammalian siderophore [2,5-dihydroxybenzoic acid (2,5-DHBA)] (Bao et al., 2010; 
Devireddy et al., 2010) and to be able to deliver this iron to cells in culture, independently of transferrin 
delivery system (Yang et al., 2002). In fact, a model of iron trafficking by LCN2 was proposed, where 
LCN2 lacking iron (apo-LCN2) binds to 24p3 receptor (24p3r), is internalized and binds to an 
intracellular mammalian siderophore, chelates iron and is exocytosed from the cell, decreasing 
intracellular iron concentration. On the contrary, holo-LCN2 binds to 24p3r, is internalized, traffics to 
endosomes and releases iron from the complex, thereby increasing intracellular iron concentration. 
Importantly, this LCN2-mediated modulation of cell iron content has been shown to impact on cell 
proliferation and apoptosis , since apo-LCN2 internalization results in apoptosis and cell death through 
the pro-apoptotic B cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (BIM) protein (Devireddy 
et al., 2005).  
1.6.1 Lipocalin-2 and CNS 
In what concerns LCN2 and CNS, current literature is not consensual in defining the real function of 
LCN2, neither by which cells it is produced. In response to a peripheral immune challenge, such as the 
intraperitoneal injection of LPS, Lcn2 expression is quickly upregulated in the CP, which is a thin 
membrane present in the brain ventricles that produces the majority of the CSF. As a result of this 
upregulation, LCN2 protein levels in the CSF are also increased. Immunohistochemical stainings in the 
CP have shown positive labelling for LCN2 in some, but not all, epithelial cells, suggesting that only 
certain cells express detectable amounts of LCN2, at least at a given moment. In this study, also the 
endothelial cells seemed to be able to produce LCN2 (Marques et al., 2008). In addition, using the 
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same LPS-injection model, another group confirmed the LCN2 production by CP-associated cells and by 
endothelial cells, but they also showed that microglial cells were able to produce it, which is 
controversial in the literature (Ip et al., 2011). The production by astrocytes is more accepted, in several 
inflammatory conditions, and even in physiological conditions (Chia et al., 2011). Cultured astrocytes 
stimulated with LPS, TNF-α and amyloid-ȕ1-42 are able to upregulate LCN2 expression and secretion (Lee 
et al., 2009; Mesquita et al., 2014). Regarding the role of LCN2 in astrocytes, it seems that LCN2 is 
able to polarize astrocytes into a more inflammatory phenotype (Jang et al., 2013). In accordance, in 
vitro studies, using astrocyte cultures, have reported increased sensitivity of these cells for NO-induced 
apoptotic death, as well as H2O2- and paraquat-induced necrotic cell death, mediated by LCN2. 
In addition, the absence of LCN2 has been reported to affect emotional and cognitive behaviour. 
Specifically, when compared to wild-type (WT) animals, 10-weeks old male LCN2-null mice presented 
anxiety and depressive-like behaviours, which were associated with increased levels of corticosterone 
production, along with mild spatial reference memory impairments. This behavioural phenotype was 
correlated with overall alterations in hippocampal neuronal morphology, suggesting a role for LCN2 in 
neuronal plasticity and behaviour (Ferreira et al., 2013).  
1.6.2 Lipocalin-2 and MS 
As for CNS diseases, LCN2 has been implicated in the pathophysiology of Alzheimer’s disease (Choi et 
al., 2011; Naude et al., 2012), pain (Jha et al., 2014) and MS (Berard et al., 2012; Marques et al., 
2012; Nam et al., 2014). Moreover, in a relapse-remitting EAE mice model, the analysis of 
transcriptome of the CP showed that Lcn2 was one of the most significantly up-regulated genes during 
the onset and relapse phases of disease, with a reduced expression during the remission phase. These 
results were correlated with high LCN2 CSF levels during the active phases of the disease, and low 
levels in the remission phase. Interestingly, aside from CP infiltrating neutrophils, astrocytes were found 
to be the only cells expressing LCN2. The production of LCN2 by the astrocytes was restricted to the 
brain areas that are typically affected in MS patients (Marques et al., 2012). Of relevance, LCN2 levels 
were also found to be elevated in CSF (Marques et al., 2012) and serum samples (Berard et al., 2012) 
from MS patients, when compared with healthy controls.  
Specifically for MOG35-55 induced EAE in LCN2-null mice, the published results are contradictory. Berard 
and colleagues (2012) have shown that LCN2-null mice induced with EAE present a more severe 
disease and pro-inflammatory response, when compared to WT induced animals (Berard et al., 2012), 
while Nam and co-workers (2014) reported that induced LCN2-null mice presented a significant 
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decrease in disease severity accompanied by reduced inflammatory infiltration, glial activation, 
inflammatory cytokine/chemokine expression, demyelination in the spinal cord and autoreactive T cell 
proliferation (Nam et al., 2014). 
Nevertheless, taking into account all the known functions of LCN2, there is no doubt that it plays a role 
in CNS inflammation, specifically in autoimmune diseases like MS. For that reason, in our study we 
intend to further understand and clarify if LCN2 plays a detrimental or protective role in MOG35-55-induced 
EAE. Contrary to the mentioned published data, we will give special attention to the cerebellum, which 
is a brain region known to be affected in MS, and to the thymus, not often looked at, but no less 
important if we consider that it is the organ were T cells mature. In the next section we will make a 
description of the thymus, and present the data that is known regarding its involvement in MS and EAE 
development. 
1.7 Role of the thymus in MS and EAE development 
The thymus is a primary lymphoid organ, where bone marrow derived progenitor cells undergo 
differentiation and maturation, to originate a functional T cell repertoire (Pearse, 2006). This organ is 
surrounded by a thin layer of connective tissue, which gives rise to septae, in some species, that 
partially subdivide the thymus into lobules that interconnect with each other. In mice there is no distinct 
sublobulation. The cortex is constituted by packed, small, immature lymphocytes, few epithelial cells 
and phagocytic macrophages (Pearse, 2006). These macrophages phagocyte the lymphocytes that 
present high avidity for self-antigens, and that are negatively selected to die (Takahama, 2006). The 
medulla presents less cellular density, staining paler that the cortex, and contains more mature T cells, 
which are larger and have more cytoplasm than cortical T cells (Pearse, 2006). Between the cortex and 
the medulla, it is possible to recognize a cortico-medullary region, rich in blood vessels, thought which 
the prothymocytes enter the thymus (Schuurman et al., 1997). 
During fetal development, hematopoietic stem cells migrate from the yolk sac and/or fetal liver to the 
thymus to begin thymic differentiation. In the adult thymus the differentiation process is also 
recapitulated by bone-marrow-derived stem cells that continually migrate to the thymus. However, in 
this last case there is a dynamic equilibrium between the stem cells that enter the thymus, and the 
mature cells that leave it. Early differentiation processes occur in the cortex of the thymus, and later 
ones in the medulla (Zuniga-Pflucker & Lenardo, 1996). 
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One of the first events taking place during thymocyte differentiation is the induction of CD25 expression 
in CD117+/CD44+/CD4-/CD8- thymocytes (pro-T cell stage). Thymocytes lose the expression of both 
CD44 and CD117, and increase the expression of CD25 (early pre-T cell stage). During this phase the 
first checkpoint of thymocyte differentiation occurs: the ȕ selection, during which there is the Tcrb gene 
rearrangement, and the cells begin to assemble TCR-ȕ and pre-TCRα chains to form the pre-TCR 
complex (Zuniga-Pflucker & Lenardo, 1996). If TCR gene rearrangement has been successful, 
thymocytes differentiate to double positive (DP) cells, which lose expression of CD25 and gain 
expression of either CD4 or CD8; if not, thymocytes die by apoptosis (late pre-T cell phase) (Michie & 
Zuniga-Pflucker, 2002; Takahama, 2006). Still in the cortical layer of the thymus, there is TCR 
engagement with MHC class I or class II molecules, resulting in positive selection (Goldrath & Bevan, 
1999). The positive selection process ensures that thymocytes have a minimal reactivity for self-
peptides, allowing only the further maturation of cells restricted to self-MHC. On the other hand, 
thymocytes that present high-avidity interactions to self-peptides are negatively selected and are further 
eliminated by apoptosis (Savage & Davis, 2001). This process of negative selection is very important for 
preventing autoimmunity, since it allows the elimination of the self-reactive T cells. There are also DP 
thymocytes that fail to receive TCR signals and are also destined to die at this stage (Takahama, 2006). 
The low-affinity recognition of self-MHC during the positive selection is also responsible for determining 
commitment to either the CD4 or CD8 lineage. Recognition of MHC class I results in CD8+ T cells, 
while the recognition of MHC class II results in CD4+ T cells  (Goldrath & Bevan, 1999). Thymocytes 
that have been positively selected, and have committed to a CD4 or CD8 lineage, go to the medullary 
layer and interact with thymic epithelial cells to complete thymocyte maturation (Takahama, 2006). At 
the medulla, self-reactive thymocytes that have escaped negative selection in the cortex are further 
deleted. This additional deletion is particularly important in establishing central tolerance to tissue-
specific antigens. The survival single positive cells are then exported from the thymus into circulation 
(Takahama, 2006). 
Even after two negative selection checkpoints, at the cortex and the medulla of the thymus, some auto-
reactive T cells are able to escape to the periphery. For example, encephalitogenic peptides, like the 
MBP NAc1-11 peptide, were found to bind weakly to MHC, forming unstable peptide/MHC complexes. 
In this case the negative selection of the T cells specific for this peptide is not efficiently mediated, 
allowing some of them to escape to the periphery (Song et al., 2006). Nevertheless, in the periphery 
the activity of auto-reactive T cells is controlled by regulatory T (Treg) cells, avoiding autoimmune 
diseases. Treg cells recognize mainly self-antigens, but they don’t proliferate after encountering these 
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antigens – they are in an anergic state. Instead, when activated, Treg cells inhibit the proliferation of 
effector T cells in their surroundings (Rose, 1994). Hence, the thymus plays an important role in the 
control of organ-specific autoimmunity by limiting the development of autoreactive T cells, for which the 
tolerance to self-antigens is essential, and also by generating Treg cells. Of notice, an inverse 
correlation between MBP expression in the thymus and EAE susceptibility was found (H. Liu et al., 
2001).  
The role of thymus in EAE has previously been addressed by different authors with thymectomized 
animals. The EAE induction in animals thymectomized soon after birth or at a young age showed a 
significant delay in disease onset. In contrary, animals thymectomized 10 days after EAE induction did 
not present differences in the course or characteristics of disease when compared with sham 
thymectomized animals (Flechter et al., 1984). In another study, after thymectomy or sham surgery 
performed at 6 weeks of age, both groups of animals developed a similar disease course. However, 
after day 16 post-disease induction, the animals subjected to sham surgery presented an improvement 
in their clinical score, unlike thymectomized animals. This recovery was probably due to accelerated 
differentiation and proliferation of thymic CD4+ forkhead box p3 (Foxp3)+ Treg cells. In thymectomized 
animals, the recovery from EAE was severely impaired due to the absence of new Treg cell emigrants, 
which suggested that the pre-existing peripheral Treg pool alone was not sufficient for complete 
regulation of pathogenic T cells (Chen et al., 2009). So it seems that the thymus plays a pivotal role in 
EAE development, and that the age at the time of thymectomy influences the resistance or susceptibility 
for EAE establishment. 
Although, it is widely recognized the vital role of the thymus in MS/EAE pathogenesis, it is still lacking a 
characterization of this organ in the WT C57BL/6 mice induced with EAE, namely regarding thymocyte 
populations and thymus histological morphology during disease onset and development, which we will 
also address in this thesis. In addition, the impact of LCN2 on this process will be evaluated. 
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1.8 Research objectives  
Although, the initial and principal aim of the present thesis is to assess whether and how LCN2 
modulates the severity of MS, because there is still limited amount of information regarding the 
alterations that occur in the thymus during disease development, even in WT mice, our first objective is 
to: 
1. Characterize the main thymic populations and the histological morphology of the thymus, in WT 
C57BL/6 mice induced with EAE, at the onset and chronic phases disease. 
To address the need to better understand the role of LCN2 in the pathophysiology of MS we will take 
advantage of the EAE model and of the mouse targeted deletion of Lcn2, and considering that most 
EAE studies are focused on the spinal cord, and few have studied the cerebellum, an area known to be 
affected in MS disease, we proposed to: 
2. Study, in the cerebellum, the expression of inflammatory cytokines, evaluate the presence of 
inflammatory infiltrates and explore astrocytic activation, at the onset and chronic phases of 
disease, after inducing EAE in LCN2-null mice and WT littermates. Also, we will address the 
thymus to unravel the impact of LCN2 in the T cell differentiation and maturation. 
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2. EXPERIMENTAL PROCEDURES 
2.1 Mice 
All experiments were conducted in accordance with the Portuguese national authority for animal 
experimentation, Direcção Geral de Veterinária (ID: DGV94457). Animals were housed and handled in 
accordance with the guidelines for the care and handling of laboratory animals in the Directive 
2010/63/EU of the European Parliament and of the Council. Efforts were made to minimize the 
number of animals used and their suffering. 
The animals were housed and maintained in a controlled environment at 22-24ºC and 55% humidity, 
on 12 hours light/dark cycles (lights on at 8 a.m.) and fed with regular rodent’s chow and tap water ad 
libitum. 
Experiments were performed using mice with a target deletion of the Lcn-2 gene (LCN2-null animals) 
and their respective littermate controls, the WT animals. These mice were obtained from LCN2 
heterozygous mattings, which in turn were obtained by breeding WT animals with LCN2-null mice in 
which the coding sequence (exons 2 to 5) of the gene that encodes for LCN2 was replaced by a 
neomycin cassette (Figure 2) (Flo et al., 2004). All the animals used were raised in a C57BL/6J 
background. 
 
 
Figure 2 - Generation of LCN2-null mice. The entire coding sequence of the LCN2 gene was replaced by a neomycin cassette. (Adapted 
from Flo et al., 2004). 
2.1.1 Genotyping  
For the LCN2-null mice and respective WT littermates, animals’ selection occurred after confirming their 
genotype by polymerase chain reaction (PCR). After collecting a tissue sample from the animals (ear, 
tail or toe sample), DNA was extracted using a DNA extraction kit (F-140; Life Technologies, Thermo 
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Fisher Scientific, Waltham, MA, USA). Briefly, the samples were incubated with 10μL of Dilution Buffer 
and 0.5μL of DNARelease Additive for 5 minutes at room temperature (RT). The tubes were then placed 
into the pre-heated block at 98ºC for 2 minutes, centrifuged and the supernatant containing the DNA 
quantified using the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific).  
The genotype PCR reaction and the detection of both mutated and WT alleles was performed using a 
common primer, which in combination with either the WT primer or the neo1500 primer allows to 
distinguish the WT from the LCN2-null mice, respectively (Figure 3). 
 
 
Figure 3 - Schematic representation of the genotype strategy for LCN2-null mice. The combination of Common and WT primers or 
Common and neo1500 were used to amplify the WT and the mutated alleles, respectively. (Adapted from Flo et al., 2004). 
 
The sequences of the 3 primers used are presented in Table 1. 
  
Table 1 – Primers’ sequence for genotyping LCN2-null animals and littermates. 
MT, melting temperature. 
 
Considering that the amplification products for both the WT and the mutated alleles have equal 
molecular weights (500bp), two independent PCR reactions were done for each sample. For each PCR 
reaction, 1μL of DNA (approximately at 100ng/μL) was added to 19μL of PCR mix, using the reagents 
described in Table 2. The reaction took place in a Primus 96 Plus Thermal Cycler (MWG Biotech, 
Ebersberg, Germany) using the conditions also presented in Table 2. 
 
Primer abbreviation Primer sequence MT (ºC) 
Common 5’ – CAC ATC TCA TGC TGC TCA GAT AGC CAC – 3’ 
58 Wild-type 5’ – GTC CTT CTC ACT TTG ACA GAA GTC AGG – 3’ 
Neo1500 5’ – ATC GCC TTC TAT CGC CTT CTT GAC GAG – 3’ 
Common 
Common Wild-type 
neo1500 
WT allele 
Mutated allele 
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Table 2 – Volume of reagents and PCR reaction conditions used for the genotyping PCR reaction. 
1 95284, Sigma-Aldrich®; 2 Fermentas Life Science, CA, USA;  3Primer Common; 4Primer Wild-type or Neo1500 
 
The PCR amplification products were electrophoresed on a 1% agarose gel, after staining with 
GreenSafe Premium (MB13201; NZYTech, Lda., Genes and Enzymes, Lisboa, Portugal), and detected 
under UV light using a Gel DocTM EZ Imager (Bio-Rad Laboratories, Hercules, CA, USA). The WT and the 
LCN2-null mice were identified for presenting only one band, for one of the PCR reactions, while the 
heterozygous animals presented 2 bands. 
2.1.2 EAE induction 
Experimental autoimmune encephalomyelitis (EAE) was induced in the animals with the Hooke KitTM 
MOG35-55/CFA Emulsion PTX (EK-2110; Hooke Laboratories, Lawrence, MA, USA). For that, LCN2-null 
females and respective WT littermates, at 10-16 weeks of age were subcutaneously injected with an 
emulsion of MOG35-55 in Freund’s complete adjuvant (CFA), at the upper and lower back of the animal, 
followed by an intraperitoneal administration of pertussis toxin (PTX) in PBS, at a final concentration of 
217ng/mL, after 2 and 24 hours of immunization. Non-induced animals, both WT and LCN2-null mice, 
were injected subcutaneously with an emulsion of PBS in CFA (263810; Difco Laboratories, Detroit, 
USA), and were also injected with PTX at the same time as the EAE animals (Figure 4). 
Master mix (vol. 20μL) Volume/μL DNA template PCR conditions 
H2O (Milli Q) 1 14.5 
1 μL 
(100ng/μL) 
95ºC 2’ 
95ºC 1’ 
58ºC 45’’      30 cycles 
72ºC 1’ 
72ºC 5’ 
4ºC ∞ 
Taq buffer (with (NH4)2SO4) 2 2 
MgCl2 (25mM) 1.2 
dNTPs (10mM) 0.4 
Primer 1 (10μM) 3 0.4 
Primer 2 (10μM) 4 0.4 
Taq polymerase (5U/μL)2 0.1 
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Figure 4 - Schematic representation of the experimental groups and the EAE induction protocol. 
 
All animals were daily weighted and monitored for clinical symptoms of disease, in a blinded way. 
Disease severity was scored according to the scale previously described by Stromnes and Goverman 
(Stromnes & Goverman, 2006), with few changes, as follows: 0=no clinical signs; 0.5=partially limp tail; 
1=paralyzed tail; 1.5=at least one of the hind legs falls through consistently when the animal is dropped 
on a wire rack; 2=loss in coordinated movement, wobbly walk; 2.5=dragging of the hind 
limbs;3=paralysis of both hind limbs; 3.5=hind limbs paralyzed and weakness in forelimbs; 4=complete 
hind limbs paralysis and partial forelimbs paralysis; 4.5=animal is not alert, no movement; 5=moribund 
state or found dead.  
2.1.3 Sample collection 
For biological sample collection, a group of EAE animals, both WT and LCN2-null mice, were sacrificed 
at the onset phase of disease (16 days after EAE induction), and another at the chronic phase of 
disease (21 or 23 days after EAE induction). Non-induced animals, from both genotypes, were 
sacrificed following the same experimental timepoints. Animals were anesthetized with ketamine 
hydrochloride (150mg/Kg) plus medetomidine (0.3mg/Kg). Blood was collected from the inferior vena 
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cava for posterior analysis, and animals were transcardially perfused with cold saline. Tissues collected 
included the brain, the thymus and the spinal cord. 
Brains collected were either macrodissected, for further gene expression studies, or immediately 
embedded in Tissue-Tek® O.C.T.TM compound (4583; Sakura Finetek, Japan), frozen on liquid nitrogen 
and kept frozen at -20ºC until further processing for immunohistochemistry analysis. In the 
macrodissected brains, regions such as the cerebellum, hippocampus and hypothalamus were 
collected. 
Similarly, the animals’ thymi were collected and snap-frozen on dry ice, for gene expression studies, or 
harvested and dissociated for flow cytometry. Also thymus from WT animals, induced or not with EAE, 
were collected to evaluate histological alterations. Half of the tissue was fixated in PFA 4% and 
impregnated in paraffin, and the other half was embedded in Tissue-Tek® O.C.T.TM compound and frozen 
in liquid nitrogen, and kept at -20ºC until posterior processing.  
2.2 Flow cytometry 
For flow cytometric analysis, the thymus of the animals was mechanically disrupted in a 6 well-plate, 
using 3mL of DMEM with 10% FBS. The medium was then transferred to a 15mL falcon and, after 
sedimentation, the supernatant, which contained the cells, was transferred to a new falcon. The tubes 
were then centrifuged and the pellet was resuspended in 2mL of FACS buffer. To count the total 
number of cells, the suspension was diluted 1:100 in a 96 well-plate, in FACS buffer, and 7-ADD was 
added. After 10 minutes of incubation, cells were counted in the MUSE® cell analyser (Merck Millipore, 
Darmstadt, Germany). 
The flow cytometry analysis was performed using 1x106 cells, that were incubated with a mix of the 
following primary antibodies: Brilliant Violet 421-anti-CD3 (clone 145-2C11, 1:100; BioLegend, San 
Diego, CA, USA), PercpCy5.5-anti-CD4 (clone RM 4-5, 1:400; BioLegend) and V500-anti-CD8 (clone 53-
6.7, 1:50; BD Biosciences, Franklin Lakes, NJ, USA). After the incubation, samples were washed twice 
with FACS buffer (0.5% BSA in PBS buffer, 0.01% Azide) and resuspended in 200μL of FACS buffer. All 
samples were acquired on a BD LSR II flow cytometer using FACS DIVA software (BD Biosciences). 
Three independent sets of animals were used, with a total of 43 WT and 41 LCN2-null mice. Data were 
analysed using FlowJo software (Tree Star, Ashland, OR, USA). The gating strategy (Figure 5) was as 
follows: single cells were gated using the FSC-H vs. FSC-A plot; cell debris were excluded using the SSC-
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A vs. FSC-A plot; the CD4 and CD8 single positive, DP and DN populations were gated in the CD8 vs. 
CD4 plot within total cells; the expression of CD3 was evaluated within the single positive populations.  
 
Figure 5 - Gating strategy used in the flow cytometry analysis. 
2.3 Gene expression analysis 
The expression levels of genes of interest were evaluated using real-time quantitative PCR (qRT-PCR). 
Total RNA was extracted from the cerebellum using TRIzol® reagent (15596; Life Technologies), 
according to the manufacturer’s instructions. Briefly, 1mL of TRIzol® was added to the frozen tissue, 
which was mechanically disrupted using a 20G needle, after which 200μL of chloroform were added. 
The two solutions were mixed and samples were incubated 2-3 minutes at RT. After centrifugation, 3 
phases were visible: an upper aqueous phase, which contains the RNA, a lower red phenol-chloroform 
phase and an interphase, which contain DNA and proteins. The upper phase was transferred into a new 
eppendorf tube, and 500μL of isopropanol were added to precipitate the RNA. Samples were incubated 
10 minutes at RT. After centrifugation, the RNA pellet was washed with 75% ethanol and dissolved in 10 
μL of nuclease free water (W4502; Sigma-Aldrich®). RNA quantification was performed using the 
NanoDrop spectrophotometer and diluted to a final concentration of approximately 1μg/μL. 
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Before the synthesis of cDNA, 4μL of RNA were treated with DNase, to eliminate possible DNA 
contamination. Briefly, the RNA was added to a RNase free tube, together with 10x reaction buffer with 
MgCl2 (B43; Life Technologies), DNase I 1U/μg (EN0525; Life Technologies) and nuclease free water, 
and incubated at 37ºC for 30 minutes. After adding 0.5M EDTA (R1021; Life Technologies) the tubes 
were placed in the pre-heated block at 65ºC for 10 minutes. The tubes were then transferred to ice and 
the RNA was quantified again. 
500ng of RNA from each sample were reverse transcribed into cDNA using the commercial kit iScriptTM 
cDNA synthesis kit (170-8890; BioRad Laboratories, Hercules, CA, USA).  Briefly, the RNA was added 
to a PCR tube, plus iScript reaction mix, iScript reverse transcriptase and nuclease free-water (Table 4). 
The reverse transcription reaction occurred in a Primus 96 Plus Thermal Cycler (MWG Biotech), 
accordingly to the conditions presented in Table 3. 
 
Table 3  - Mix and reaction conditions used for the RT-PCR. 
RT-PCR reagent Volume (μL)/reaction RT-PCR conditions 
RNA Corresponding to 500ng of RNA 5 minutes at 25ºC 
30 minutes at 42ºC 
5 minutes at 85ºC 
∞ at 4ºC  
5x iScript reaction mix 4 
iScript reverse transcriptase 1 
Nuclease-free water Until a final volume of 20μL 
 
qRT-PCR was performed on a CFX96TM Real-Time System instrument (Bio-Rad Laboratories), with the 
commercial kit SsoFastTM EvaGreen® Supermix (172-52; BioRad Laboratories), according to the 
manufacturer’s instructions (Table 4), using equal amounts of cDNA from each sample. Briefly, for 
each sample a mix was prepared with 3μL of nuclease-free water, 5μL of SsoFastTM EvaGreen® 
Supermix and 0.5μL of each primer. Product fluorescence was detected at the end of the elongation 
cycle. All melting curves exhibited a single sharp peak at the expected temperature. The reference gene 
hypoxanthine guanine phophoribosyltransferase (Hprt) was used as an internal standard for the 
normalization of the expression of selected transcripts. The sequences and respective annealing 
temperatures of the selected transcripts are presented in Annex 1.  
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Table 4 - Reaction conditions used for the qRT-PCR. 
Reaction step Temperature/ºC Time/seconds Number of cycles 
Enzyme activation 95 900 1 
Denaturation 94 15 
39 Annealing 
Annealing temperature 
(primer specific) 
20 
Extension 72 20 
Melting curve 65 to 95 5 1 
2.4 Histological analysis 
2.4.1 Thymic morphology 
For histological analysis, the collected thymi from WT animals, induced or not with EAE, were 
embedded in paraffin and sectioned at 4μm. The paraffin sections were then stained with hematoxylin 
and eosin (HE), for the visualization of the cell’s nucleus and cytoplasm, respectively. 
2.4.2 Immunofluorescence for GFAP 
Brains collected at the sacrifice, during the onset and chronic phases, were sectioned at 20μm (coronal 
sections) and cerebellum sections were further selected and stained for GFAP, in order to evaluate 
astrogliosis present in the cerebellar white matter. Sections were fixed in 4% PFA in PBS for 30 minutes 
at RT. After antigen retrieval, with citrate buffer (C9999; Sigma-Aldrich®) in the microwave for 20 
minutes, the tissue was permeabilized with PBS-Triton 0.3% at RT for 10 minutes and subsequently 
blocked with 10% fetal bovine serum (FBS) in PBS-triton 0.3% at RT for 30 minutes. For the 
immunofluorescent staining for GFAP, slides were incubated overnight with rabbit anti-mouse GFAP 
antibody (1:200; Dako, Denmark), diluted in PBS-triton 0.3% with 10% of FBS. The respective secondary 
fluorescent antibody Alexa Fluor® 594 donkey anti-rabbit (A21207; Life Technologies) diluted 1:500 in 
PBS-triton 0.3% was used for 2 hours at RT. Next, the slides were incubated with DAPI (1:200; 
Invitrogen, Life Techologies), cover-slipped with Immumount (99-904; Fisher Scientific, Thermo Fisher 
Scientific) and examined under fluorescent light. To quantify the total GFAP+ area, photographs were 
taken in 20 non-overlapping fields of the cerebellar white matter, using a fluorescent microscope (BX61, 
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Olympus, Hamburg, Germany), and analysed using the Fiji software (Schindelin et al., 2012). For each 
animal, it was calculated the average of GFAP+ area in the total number of photographs.  
2.4.3 Luxol Fast Blue 
The histochemical staining Luxol Fast Blue was used to evaluate lesioned sites, with inflammatory 
infiltrates, in the cerebellum. Selected frozen sections of cerebellum were fixated in 95% ethanol at RT 
for 15 minutes, and stained in 0.1% luxol fast blue MBS (1B-389; Chroma-Gesellshaft, Schmidt 
Gmbh+Co, Köngen, Germany) in 0.5% glacial acetic acid with 95% ethanol solution, over-night at 56ºC. 
The excess of dye was removed using first 95% ethanol and then running water. Slides were 
differentiated with 0.05% lithium carbonate (62470; Sigma-Aldrich®) for 10 minutes and with 70% 
ethanol for 10 seconds, counterstained with hematoxylin, dehydrated and mounted with Entellan® 
(107961; Merck Millipore).  
The quantification of demyelination was done in representative sections of the entire cerebellum 
(minimum of 7 cerebellum sections examined per animal), using an Olympus microscope and the 
Stereo Investigator software (MBF Bioscience, Williston, Vermont, USA). The total white matter area was 
drawn using an objective of 4x and the demyelination areas were delimitated using the objective of 10x. 
The percentage of demyelination was determined by dividing the sum of the demyelination areas by the 
total white matter area, multiplied by 100. 
2.5 Serum corticosterone quantification 
Blood was collected during the sacrifice and was posteriorly centrifuged, for 10 minutes at 13000rpm, 
and serum was collected and stored at -80ºC. Subsequent corticosterone quantification was performed 
using a commercial ELISA kit (ADI-901-097; Enzo Life Sciences, Inc., Farmingdale, NY, USA), according 
to the manufacturer’s instructions. Briefly, samples were incubated with a specific antibody for 
corticosterone and a known concentration of corticosterone labelled with alkaline phosphatase, which 
competed with the sample corticosterone for the binding sites of the antibodies. After washing the 
unspecific binding, a substrate of alkaline phosphatase was added to the wells and the reaction 
originated a coloured solution. The optical density (OD) of the wells was read using a Microplate Reader 
(Model 680, BioRad Laboratories). The samples corticosterone concentration was calculated using the 
GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA), after fitting a 4 parameter logistic 
curve to the standards ODs. 
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2.6 Statistical analysis 
Results were analysed using GraphPad Prism 6.0, and statistical significance was considered for 
p<0.05. In the first set of results, where we aimed to address the thymic response only in WT mice, to 
compare different WT groups (non-induced, EAE onset and EAE chronic) a one-way ANOVA was used. In 
the second set of results, to compare WT and LCN2-null mice, non-induced or at the onset or chronic 
phases of EAE a two-way ANOVA was used. To compare disease measurements (day of first score, day 
of score=3, first score different from 0) between EAE LCN2-null and WT mice a t-test for independent 
samples was used. The Kolmogorov-Smirnov test was used to test the normality of the distribution of 
the samples. When a suitable non-parametric test was not available a parametric test was used, even if 
the samples did not presented a normal distribution. Differences between groups were determined by 
Bonferroni’s multiple comparison test post hoc analysis. All values are expressed as mean±SEM and as 
the average of all the experiments performed.  
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3. RESULTS  
3.1 Chronic disease course in MOG35-55 induced EAE  
After EAE induction with MOG35-55 WT animals developed a chronic disease course, with the first 
symptoms appearing at around day 11 (Figure 6A), coincidently with the beginning of weight loss by 
these animals (Figure 6B). The EAE animals lost about 20% of their initial weight between days 11 and 
17, which is when the chronic phase of disease begins. At day 16 the disease was at the peak of 
activity, while at day 23 the animals were already in a chronic phase, which is why these timepoints 
were chosen as endpoints for the experiments. 
 
 
Figure 6 - Disease course of MOG35-55-induced EAE in WT animals. EAE WT animals induced with MOG35-55 presented the first symptoms at 
day 11 post-disease induction, at around day 16 the disease reached a peak of activity, and after that the animals remained with a similar 
score until the end of the experiment, at day 23 (chronic phase of disease) (A). The EAE animals started losing weight after the 
appearance of the first symptoms, at day 11 (B). (From day 0 to day 16 post-EAE induction: nnon-induced=37, nEAE=46; from day 17 to day 23 
post-EAE induction: nnon-induced=10, nEAE=15. Data presented as mean±SEM). 
3.2 The proportion of the four main populations of the thymus was altered in WT 
animals during the onset phase EAE but was restored in the chronic phase of 
disease 
To assess alterations in the thymus populations during the EAE course we collected the animals’ thymi 
during the sacrifice and performed flow cytometry in WT animals induced with EAE, and used non-
induced animals as controls. Animals were sacrificed at the onset and chronic phases of disease. The 
EAE animals presented thymic atrophy, at both timepoints, as assessed by thymus weight, normalized 
for total body weight (non-induced=0.002218±0.0000996, EAE onset=0.000532±0.0001433, EAE 
chronic=0.000655±0.0001631; F(2,12)=46.48, p<0.0001) (Figure 7A), and total cell number (non-
induced=10.92±0.625x107, EAE onset=2.09±0.932x107, EAE chronic=2.52±0.502x107, F(2,40)=50.58, 
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p<0.0001)  (Figure 7B). Also the percentage of viable cells, evaluated by lack of 7-ADD staining and 
counted in the MUSE® cell analyser, was decreased in EAE animals (non-induced=86.80±1.571, EAE 
onset=77.79±1.891, EAE chronic=76.79±3.167, F(2,40)=7.914, p=0.0013)  (Figure 7C). 
Thymocytes were stained for CD3, CD4 and CD8, to distinguish the 4 main populations present in the 
thymus, namely the DN, DP and single positive, for CD4 or CD8, populations. A representative CD4 vs. 
CD8 plot for each of the groups analysed is presented in Figure 7D. During the onset phase of disease 
the percentage of the four populations was altered, having occurred a significant decrease in the DP 
cells (non-induced=83.27±0.747, EAE onset=27.24±8.039, EAE chronic=68.29±7.705, F(2,40)=29.95, 
p<0.0001), and an increase in both single positive populations (CD4+CD8-: non-induced=6.63±0.411, 
EAE onset=40.63±5.171, EAE chronic=8.34±2.990, F(2,40)=36.84, p<0.0001; CD4-CD8+: non-
induced=1.42±0.114, EAE onset=7.76 ±1.466, EAE chronic=2.763±1.466, F(2,40)=13.53, p<0.0001). 
The percentage of these populations was re-established to control levels in the chronic phase. 
Regarding the DN population there was an increase along disease development (non-
induced=2.12±0.161, EAE onset=8.98±1.095, EAE chronic=10.05±2.836, F(2,40)=12.04, p<0.0001) 
(Figure 7E).  
As for the absolute numbers of the four populations, they were decreased in EAE animals, at both 
timepoints, when compared to non-induced mice, which could be a consequence of the decrease in the 
total cell number (DN: non-induced=2.32±0.240x106, EAE onset=1.13±0.208x106, EAE 
chronic=1.77±0.394x106, F(2,40)=5.511, p=0.0077; DP: non-induced=90.99±5.453x106, EAE 
onset=12.00±8.202x106, EAE chronic=19.28±4.292x106, F(2,40)=51.08, p<0.0001; CD4+CD8-: non-
induced=6.91±0.404x106, EAE onset=4.65±0.621x106, EAE chronic=1.46±0.416x106, F(2,40)=27.67, 
p<0.0001; CD4-CD8+: non-induced=1.45±0.080x106, EAE onset=0.90±0.143x106, EAE 
chronic=0.36±0.112x106, F(2,40)=23.09, p<0.0001) (Figure 7F). Interestingly, although in the chronic 
phase of disease the total cell numbers were decreased, like in the onset phase, there was a re-
establishment of the proportions between the four populations to the levels of non-induced animals.  
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Figure 7 – Thymus flow cytometry results. Animals induced with EAE presented thymic atrophy, as assessed by the thymus weight, 
normalized for total body weight (A), and the total cell number per μL, counted in the MUSE® cell analyser (B). The percentage of viable 
cells was decreased in EAE animals (C). Representative CD4 vs. CD8 plots of the control group (left D) and EAE groups, at the onset 
phase of disease (middle D) and chronic phase (right D), showed differences in thymocyte populations between the groups. The 
percentage of double positive cells decreased at the onset of disease, while the percentage of both CD4 and CD8 single positive 
populations increased, compared with non-induced animals. At the chronic phase of disease the percentage of these populations was 
restored to the levels of non-induced animals. The percentage of double negative cells increased with disease development (E). The total 
cell number per μL of all populations decreased along disease development, which could be a consequence of the decreased total cell 
number (F). (nnon-induced=19, nEAE onset=14, nEAE chronic=10. Data presented as mean±SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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3.2.1 Corticosteroid measurement 
Previous studies have reported that the activation of the hypothalamic-pituitary-adrenal (HPA) axis, 
during stressful stimuli or pathological conditions can induce thymic atrophy, characterized mainly by 
acute loss of cortical DP thymocytes. (Gruver & Sempowski, 2008). For that reason, we next quantified 
corticosterone concentration in the serum of the animals, at the day of sacrifice. The corticosterone 
levels although not significantly different, tend to be higher in EAE induced mice compared with non-
induced mice (non-induced=23.05±2.479, EAE onset=41.40±10.330, EAE chronic=34.84±7.179, 
F(2,12)=1.579, p=0.2461) (Figure 8). 
 
Figure 8 – Corticosterone serum concentration at the sacrifice day. EAE animals, at both timepoints, did not present statistically significant 
increased levels of corticosterone at the day of sacrifice. (nnon-induced=5, nEAE onset=5, nEAE chronic=5. Data presented as mean±SEM). 
3.3 Thymic histological morphology was altered in WT EAE animals 
The thymus is morphologically divided in cortex and medulla, which are separated by a vascular 
corticomedullary zone. After observing a decrease in the percentage of DP cells, during the onset phase 
of disease, we next went to assess the consequences in thymic morphology. Macroscopically, the thymi 
of WT EAE animals were decreased in size, resulting in a decreased weight, even after normalization for 
total body weight (Figure 7A), when compared to non-induced animals. In non-induced animals, the 
thymus presented a normal morphology, with clearly distinctive areas of cortex and medulla (Figure 9, 
left panel). In WT EAE animals, in the initial phases of disease development when they present lower 
clinical scores (clinical score=1), although the decrease in the thymus weight, the thymic morphology is 
still similar to non-induced animals, being possible the distinction between areas of cortex and medulla 
(Figure 9, middle panel), while in more advanced stages of the disease, when the animals are already 
paralyzed (clinical score=3), the medulla is almost inexistent (Figure 9, right panel). 
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Figure 9 – Histological morphology of the thymus in WT non-induced and EAE animals at the onset phase of disease. Non-induced 
animals present a normal histological morphology of the thymus, with distinct areas of cortex and medulla. In EAE animals, at earlier 
stages of disease the morphology is similar to non-induced animals, while in later stages the areas of medullary tissue is scarce (upper 
panel bar=200μm; lower panel bar=50μm). 
3.4 Disease course in LCN2-null mice was similar to WT animals 
EAE was induced in LCN2-null mice with the same protocol used for WT animals. We did not observe 
significant differences between LCN2-null and WT mice in overall disease development (Figure 10A), 
nor in specific disease measurements, such as the mean day when the animals presented the first 
symptoms, the mean day when they reached a clinical score of 3, i.e., when the animals became 
paralyzed, and the mean first score of disease given to the animals (Table 5). Also, the body weight 
variances along the experiment were similar in both genotypes (Figure 10B). Regarding disease 
incidence, only one animal of each genotype did not develop disease symptoms, and they were 
subsequently excluded from all the analysis. 
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Figure 10 – Disease course of MOG35-55--induced EAE in LCN2-null mice and WT littermates. In LCN2-null mice the disease course is similar 
to WT littermates, with no significant differences between the clinical scores of both genotypes (A). LCN2-null EAE mice also lose weight in 
a similar way as the WT EAE animals (B). (From day 0 to day 16 post-EAE induction: nnon-induced WT=37, nEAE WT=46, nnon-induced LCN2-null=38, nEAE LCN2-null=37; 
from day 17 to day 23 post-EAE induction: nnon-induced WT=10, nEAE WT=15; nnon-induced LCN2-null=15, nEAE LCN2-null=11. Data presented as mean±SEM). 
 
 
Table 5 – EAE progression in LCN2-null mice and WT littermate mice. 
 Incidence 
Day of 1st symptoms 
(n) 
Day of clinical score=3  
(n) 
1st clinical score  
(higher than 0) (n) 
WT 37/38 12.35±0.170 
(37) 
14.65±0.220 
(31) 
1.08±0.091 
(37) 
LCN2-null 28/29 12.43±0.319 
(28) 
14.52±0.332 
(23) 
0.89±0.099 
(28) 
t test value  t(63)=0.2279 t(52)=0.3220 t(63)=1.6416 
p value  0.8205 0.7487 0.1057 
3.5 LCN2-null mice presented similar alterations to the WT animals regarding thymic 
populations, during EAE development 
The thymi of LCN2-null mice were processed for flow cytometry analysis the same way as for WT 
animals, to evaluate if LCN2 absence influences the thymic response in the context of EAE. LCN2-null 
mice present similar CD4 vs. CD8 plots to the WT animals, both for the non-induced animals and for 
the EAE animals, at the onset and chronic phases of disease (Figure 11A). The percentage of CD4 and 
CD8 single positive cells increased in LCN2-null mice at the onset phase of disease, and was restored 
to the levels of non-induced animals at the chronic phase, while the percentage of DN increased along 
disease progression. As for the percentage of DP cells, it decreased at the onset phase and increased 
again at the chronic phase. Of notice, the percentage of DP cells in the LCN2-null mice during the 
chronic phase was still significantly lower than non-induced animals (Table 6 and Figure 11B). The 
LCN2-null EAE animals presented a decrease in the cell number of all thymocyte populations, at both 
phases of EAE, except for the DN cells, similarly to what happed in WT animals (Table 7 and Figure 
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11C).To sum up, for both the thymus cell numbers and percentages, we only observed a significant 
effect of the disease factor, with neither the genotype nor the interaction between factors presenting a 
significant influence in the thymic populations (Tables 6 and 7). 
 
 
← Figure 11 – Flow cytometry results in LCN2-null and WT mice. Representative CD4 vs. CD8 plots of the WT control group (left up A), 
WT onset (middle up A), WT chronic (right up A), LCN2-null control (left down A), LCN2-null onset (middle down A) and LCN2-null chronic 
(middle down A). Flow cytometric analysis of the LCN2-null mice thymus shows similar results to the WT animals, indicating that the lack 
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of LCN2 does not influence thymocytes number (B) nor the thymus populations percentages (C) during EAE development (nnon-induced WT=19, nEAE 
onset WT=14, nEAE chronic WT=10, nnon-induced LCN2-null=20, nEAE onset LCN2-null=11, nEAE chronic LCN2-null=10. Data presented as mean±SEM. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001). 
 
 
Table 6 - Two-Way ANOVA results for the comparison of thymus population’s percentages between LCN2-null and WT mice. 
    Mean±SEM Disease factor 
Genotype 
factor 
Interaction 
P
e
rc
e
n
ta
g
e
 o
f 
ce
lls
 
D
N
 
W
T
 
Non-induced 2.12±0.161 
F(2,76)=42.70, 
p<0.0001 
F(1,76)=0.7023, 
p=0.4046 
F(2,76)=0.2194, 
p=0.8035 
EAE onset 8.98±1.095 
EAE chronic 10.05±2.836 
L
C
N
2
-n
u
ll Non-induced 2.49±0.143 
EAE onset 12.14±2.252 
EAE chronic 14.27±5.136 
D
P
 
W
T
 
Non-induced 83.27±0.747 
F(2,76)=53.54, 
p<0.0001 
F(1,76)=1.441, 
p=0.2337 
F(2,76)=0.2764, 
p=0.7593 
EAE onset 27.24±8.039 
EAE chronic 68.29±7.705 
L
C
N
2
-n
u
ll Non-induced 81.61±0.958 
EAE onset 21.43±9.635 
EAE chronic 57.81±11.200 
C
D
3
+
C
D
4
+
C
D
8
- 
W
T
 
Non-induced 6.63±0.411 
F(2,76)=66.91, 
p<0.0001 
F(1,76)=0.0144, 
p=0.9049 
F(2,76)=0.0926, 
p=0.9117 
EAE onset 40.63±5.171 
EAE chronic 8.34±2.990 
L
C
N
2
-n
u
ll Non-induced 7.157±0.559 
EAE onset 39.36±6.103 
EAE chronic 10.04±3.165 
C
D
3
+
C
D
4
-C
D
8
+
 
W
T
 
Non-induced 1.42±0.114 
F(2,76)=27.02, 
p<0.0001 
F(1,76)=0.4995, 
p=0.4819 
F(2,76)=0.1983, 
p=0.8205 
EAE onset 7.76±1.288 
EAE chronic 2.76±1.466 
L
C
N
2
-n
u
ll Non-induced 1.43±0.126 
EAE onset 8.96±2.057 
EAE chronic 3.35±1.296 
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Table 7 – Two-Way ANOVA results for the comparison of thymus cell numbers between LCN2-null and WT mice. 
    Mean±SEM 
(x106) 
Disease factor 
Genotype 
factor 
Interaction 
N
u
m
b
er
 o
f 
ce
lls
 
D
N
 
W
T
 
Non-induced 2.32±0.240 
F(2,76)=3.639, 
p=0.031 
F(1,76)=1.165, 
p=0.2838 
F(2,76)=0.6266, 
p=0.5372 
EAE onset 1.13±0.208 
EAE chronic 1.77±0.394 
L
C
N
2
-n
u
ll Non-induced 2.56±0.218 
EAE onset 1.11±0.204 
EAE chronic 3.05±1.810 
D
P
 
W
T
 
Non-induced 90.99±5.453 
F(2,76)=88.74, 
p<0.0001 
F(1,76)=0.0512, 
p=0.8217 
F(2,76)=0.5807, 
p=0.5620 
EAE onset 12.00±8.202 
EAE chronic 19.28±4.292 
L
C
N
2
-n
u
ll Non-induced 83.92±5.635 
EAE onset 7.71±5.297 
EAE chronic 26.79±9.683 
C
D
3
+
C
D
4
+
C
D
8
- 
W
T
 
Non-induced 6.91±0.404 
F(2,76)=48.51, 
p<0.0001 
F(1,76)=0.3561, 
p=0.5524 
F(2,76)=0.7636, 
p=0.4695 
EAE onset 4.65±0.621 
EAE chronic 1.46±0.416 
L
C
N
2
-n
u
ll Non-induced 7.10±0.562 
EAE onset 3.56±0.691 
EAE chronic 1.50±0.467 
C
D
3
+
C
D
4
-C
D
8
+
 
W
T
 
Non-induced 1.45±0.080 
F(2,76)=42.70, 
p<0.0001 
F(1,76)=0.7023, 
p=0.4046 
F(2,76)=0.2194, 
p=0.8035 
EAE onset 0.90±0.143 
EAE chronic 0.35±0.112 
L
C
N
2
-n
u
ll Non-induced 1.39±0.105 
EAE onset 0.71±0.152 
EAE chronic 0.34±0.100 
3.5.1 Corticosteroid measurements 
Unlike to what happened in WT animals, at the onset phase of disease, the LCN2-null mice showed an 
increase in the serum levels of corticosterone, but at the chronic phase these levels were re-established 
to the levels of non-induced animals (Figure 12). Also, during the onset phase, the corticosterone levels 
were significantly higher in LCN2-null mice compared with WT animals at the same phase of disease 
(non-induced WT=23.05±2.479, EAE onset WT=41.40±10.330, EAE chronic WT=34.84±7.179, non-
induced LCN2-null=27.70±8.026, EAE onset LCN2-null=76.46±11.670, EAE chronic LCN2-
null=37.93±13.500; disease factor: F(2,23)=7.073, p=0.004, genotype factor: F(1,23)=3.554, p=0.0721, 
interaction: F(2,23)=1.925, p=0.1687) (Figure 12). 
 43 
 
 
 
Figure 12 – Serum corticosterone concentration in LCN2-null and WT mice at the sacrifice day. At the onset of disease EAE LCN2-null 
mice present increased levels of corticosterone, compared with control LCN2-null mice and WT mice at the onset of disease, at the 
sacrifice day. (nnon-inducedl WT=5, nEAE onset WT=5, nEAE chronic WT=5, nnon-induced LCN2-null=5, nEAE onset LCN2-null=5, nEAE chronic LCN2-null=5. Data presented as mean±SEM. *p<0.05, 
**p<0.01). 
3.6 LCN2 deficiency results in a decreased inflammatory profile in the cerebellum of 
EAE animals 
Clinical studies have shown relevant cerebellar deficits in MS patients (Weinshenker et al., 1996). The 
cerebellum is mainly involved in coordination and balance, thus playing an important role in the 
modulation of movement. (MacKenzie-Graham et al., 2009). Also, even though most studies using the 
EAE animal model are focused primarily on disease in the spinal cord, the cerebellum has also been 
shown to be affected in this model (Kuerten et al., 2007; MacKenzie-Graham et al., 2006; MacKenzie-
Graham et al., 2009). For this reason we intended to characterize the inflammatory profile in the 
cerebellum of LCN2-null and WT mice, by quantifying the expression levels of inflammatory cytokines, 
especially of genes involved in the Th1 and Th17 response, and the percentage of inflammatory 
infiltrates in the white matter. 
3.6.1 Inflammatory cytokines expression levels 
The expression levels of inflammatory cytokines involved in the Th1 immune response, namely Ifn-
gamma (Figure 13A) and Il12a (Figure 13B), were increased in the cerebellum of EAE animals, during 
the onset phase of disease, and decreased in the chronic phase, in both genotypes. Of relevance, the 
increase in the expression level of Ifn-gamma in the LCN2-null mice was less expressive than in the WT 
mice, being this difference statistically significant. As for Il17a (Figure 13C), a cytokine involved in the 
Th17 response, its expression levels only increased significantly in the onset phase of disease in WT 
animals, and not in the onset phase of LCN2-null mice. Besides this, during the onset phase, and 
considering all these three genes, their expression levels is decreased in LCN2-null mice when 
comparing with WT animals (Figure 13A, B and C), which suggests a decrease in the Th1 and Th17 
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inflammatory responses in the cerebellum of LCN2-null mice, compared with WT animals. The 
expression levels of Il4, a cytokine produced by Th2 cells, was not different between EAE and non-
induced animals (Figure 13D). The results of the two-way ANOVA analysis are presented in Table 8. 
 
 
Figure 13 - Expression levels of inflammatory cytokines in the cerebellum. During the onset phase of disease, the expression levels of Ifn-
gamma (A) and Il12a (B), which are involved in the Th1 response, are significantly increased in both WT and LCN2-null mice, when 
compared to non-induced animals. At the chronic phase the expression of these cytokines decreased to the levels of non-induced animals. 
In the case of IL17a, involved in the Th17 response, it was only significantly elevated in the onset phase of disease in the WT animals (C). 
The expression levels of Il4, a cytokine involved in the Th2 response, were not altered (D). (nnon-inducedl WT=4, nEAE onset WT=5, nEAE chronic WT=5, nnon-induced LCN2-
null=5, nEAE onset LCN2-null=6, nEAE chronic LCN2-null=5. Data presented as mean±SEM. *p<0.05, **p<0.01, ***<0.001, ****p<0.0001). 
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Table 8 - Results of the two-way analysis of gene expression in the cerebellum. 
     Mean±SEM Disease factor Genotype factor Interaction 
If
n
-g
am
m
a W
T
 
Non-induced 2.21e-4±7.08e-5 
F(2,24)=19.22, 
p<0.0001 
F(1,24)=7.180, 
p=0.0131 
F(2,24)=2.647, 
p=0.0914 
EAE onset 9.75e-3±1.998e-3 
EAE chronic 3.69e-3±1.252e-3 
L
C
N
2
-n
u
ll Non-induced 9.40e-5±3.042e-5 
EAE onset 4.45e-3±1.076e-3 
EAE chronic 1.54e-3±7.09e-4 
Il1
2
a 
W
T
 
Non-induced 1.44e-5±6.25e-6 
F(2,24)=15.09, 
p<0.0001 
F(1,24)=1.471, 
p=0.2369 
F(2,24)=0.8521, 
p=0.4390 
EAE onset 1.96e-4±4.70e-5 
EAE chronic 5.85e-5±3.550e-5 
L
C
N
2
-n
u
ll Non-induced 2.46e-6±1.666e-6 
EAE onset 1.26e-4±2.78e-5 
EAE chronic 5.53e-5±1.451e-5 
Il1
7
a 
W
T
 
Non-induced 5.19e-4±2.764e-4 
F(2,24)=9.343, 
p=0.0010 
F(1,24)=3.196, 
p=0.0865 
F(2,24)=1.010, 
p=0.3790 
EAE onset 7.16e-3±2.606e-3 
EAE chronic 2.18e-3±8.39e-4 
L
C
N
2
-n
u
ll Non-induced 2.47e-4±5.51e-5 
EAE onset 3.50e-3±9.03e-4 
EAE chronic 7.56e-4±2.830e-4 
Il4
 
W
T
 
Non-induced 3.07e-3±9.20e-4 
F(2,24)=0.6162, 
p=0.5483 
F(1,24)=1.111, 
p=0.3023 
F(2,24)=0.9579, 
p=0.3979 
EAE onset 1.50e-3±3.70e-4 
EAE chronic 3.00e-3±1.235e-3 
L
C
N
2
-n
u
ll Non-induced 1.88e-3±3.62e-4 
EAE onset 1.86e-3±4.56e-4 
EAE chronic 1.65e-3±3.87e-4 
3.6.2 Inflammatory infiltrates in the cerebellum white matter 
To evaluate lesion areas in the white matter we stained representative sections of the whole cerebellum 
with the histochemical coloration luxol fast blue. Representative images of the normal cerebellum of a 
non-induced animal (left panel), and of an animal induce with EAE (right panel) are presented in Figure 
14A. For both the onset and chronic phases of disease, the lesioned areas where identified as areas 
stained lighter blue with luxol and with the presence of inflammatory infiltrates, in the white matter 
(Figure 14A, right bottom panel). The sum of lesioned areas was divided by the total white matter area, 
in order to obtain a measurement of the percentage of lesioned area. Animals from both genotypes 
presented a decrease in the percentage of lesioned area, in the cerebellum white matter, at the chronic 
phase of disease, when compared with animals at the onset phase, but this decrease was only 
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statistically significant for the WT animals (EAE onset WT=4.01±0.766, EAE chronic WT=1.36±0.339, 
EAE onset LCN2-null=2.62±0.350, EAE chronic LCN2-null=0.65±0.197; disease factor: F(1,30)=9.640, 
p=0.0041, genotype factor: F(1,30)=2.052, p=0.1623, interaction: F(1,30)=0.251, p=0.6201) (Figure 14B). 
We also found a high correlation between the percentage of lesioned areas in the cerebellum and the 
animals’ clinical score, during the onset phase of disease, for the WT animals (r=0.7537, r2=0.5681, 
p=0.0019), but not for the LCN2-null mice (r=0.5161, r2=0.2663, p=0.1268) (Figure 14C). 
 
 
Figure 14 – Luxol fast blue staining for myelin in cerebellum slices.  The cerebellum white matter of animals induced with EAE present 
lesion areas which are not seen in control animals. These areas correspond to lesioned areas and are identified after luxol fast blue 
staining as less blue areas with inflammatory infiltrates (arrows) (upper panel bar=200μm, lower panel bar=50μm) (A). At the chronic 
phase of disease the percentage of lesioned areas decreases in WT and LCN-2 null EAE animals, compared with the onset phase (B). 
During the onset phase of disease the percentage of lesioned areas correlates highly with the clinical score in WT animals, but not in 
LCN2-null mice (C) (nEAE onset WT=14, nEAE chronic WT=5, nEAE onset LCN2-null=10, nEAE chronic LCN2-null=5. WM – white matter; ML – molecular layer; GL – granular layer. 
Data presented as mean±SEM. *p<0.05). 
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3.7 Astrogliosis is increased in the cerebellum during EAE 
Previous studies have shown that, in the context of a relapse-remitting EAE model, astrocytes express 
LCN2 (Marques et al., 2012), so we evaluated if LCN2 deficiency influences astrocytic activation in the 
chronic model of EAE. To do so, we stained cerebellum slices for GFAP, and photographed 20 non-
overlapping areas of the white matter. The total GFAP+ area was assessed later using the Fiji software, 
after converting the colour images into binary images. Representative images of the GFAP staining in 
cerebellar white matter of non-induced animals and animals induced with EAE, at the onset and chronic 
phases of disease, are presented in Figure 15A. The quantification of the total GFAP+ area showed an 
increase at the onset and chronic phases of disease, both WT and LCN2-null mice induced with EAE, 
compared with non-induced animals (non-induced WT=2.46±0.756, EAE onset WT=9.31±1.381, EAE 
chronic WT=12.52±2.499, non-induced LCN2-null=0.95±0.286, EAE onset LCN2-null=12.00±2.260, 
EAE chronic LCN2-null=10.55±4.778; disease factor: F(2,12)=9.660, p=0.0032, genotype factor: 
F(1,12)=0.018, p=0.8964, interaction: F(2,12)=0.539, p=0.5967) (Figure 15B).  
We also measured the expression levels of Gfap in the cerebellum of WT and LCN2-null mice, in both 
phases of the disease, and we found an increase in its expression levels at the onset phase of disease, 
and a decrease to similar levels of non-induced animals during the chronic phase, in both genotypes 
(non-induced WT=0.0495±0.01408, EAE onset WT=0.2320±0.04622, EAE chronic 
WT=0.1289±0.02823, non-induced LCN2-null=0.0219±0.00357, EAE onset LCN2-
null=0.1883±0.02243, EAE chronic LCN2-null=0.0717±0.01088; disease factor: F(2,24)=25.560, 
p<0.0001, genotype factor: F(1,24)=3.732, p=0.0653, interaction: F(2,24)=0.328, p=0.7237) (Figure 15C). 
 
 
 
 
 
 
 
Figure 15 – GFAP immunohistochemical staining and expression levels in the cerebellum. Representative images from the cerebellum 
white matter show the presence of astrogliosis in EAE animals during the onset and chronic phases of disease (A), which lead to an 
increase in the percentage of GFAP positive area in these two phases of disease, both in WT and LCN2-null mice, when compared with 
non-induced animals (B). The expression levels of Gfap in the total cerebellum were elevated during the onset phase of disease, compared 
with the levels of non-induced animals, and decreased during the chronic phase (C). (GFAP+ area quantification: nnon-induced WT=3, nEAE onset WT=3, nEAE 
chronic WT=3, nnon-induced LCN2-null=3, nEAE onset LCN2-null=3, nEAE chronic LCN-2 null=3; Gfap  expression levels: nnon-induced WT=4, nEAE onset WT=5, nEAE chronic WT=5, nnon-induced LCN2-null=5, nEAE onset LCN2-null=6, 
nEAE chronic LCN-2 null=5. Data presented as mean±SEM. Bar=20μm. *p<0.05, **p<0.01, ***p<0.001).         → 
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4. DISCUSSION 
The work presented here was designed to characterize thymic alterations during EAE development, in a 
chronic model of disease, and also to further explore the role of LCN2 in several aspects of EAE 
progression. 
Using both WT and LCN2-null mice induced with EAE, we were able to show that when the disease in 
completely established (day 16), in the periphery, the thymus presented altered population proportions, 
and in the CNS, specifically in the cerebellum, there was increased inflammatory activity, characterized 
by increase in pro-inflammatory cytokines expression, the presence of inflammatory infiltrates and 
astrogliosis. At the chronic phase of disease (day 23), although the clinical scores of the animals had 
not improved, the thymic populations were restored, and inflammation was decreased in the 
cerebellum. 
Regarding the contribution of LCN2 to the EAE establishment and progression, in terms of clinical score 
we didn’t observed differences between LCN2-null mice and WT mice induced with EAE. Also the 
thymic response in EAE LCN2-null mice, both in day 16 and 23, is similar to the EAE WT animals. 
However a decreased inflammatory response was observed in the cerebellum of LCN2-null mice 
induced with EAE, compared with WT EAE animals, especially at the onset phase (day 16). 
4.1 Thymus characterization in the context of a chronic EAE model  
The thymus is a primary lymphoid organ, where bone marrow derived progenitor cells undergo 
differentiation and maturation, to originate a functional T cell repertoire (Pearse, 2006). Post-natally, it 
is composed of thymocytes in various states of differentiation and supporting stromal thymic epithelial 
cells (Gruver & Sempowski, 2008). The thymus is responsible for the differentiation and production of T 
helper (CD4+) or T cytotoxic (CD8+) subsets of cells, as well as Treg cells, and for that reason plays an 
important role both in the initiation and the prevention of auto-immunity mechanisms. Concerning the 
different populations of the thymus, they can be distinguished by their cell-surface markers, being the 
CD4 and CD8 markers the most important ones, along with T-cell receptor molecules. In MS it is 
generally accepted that the disease is the result of an autoimmune response against CNS antigens. 
Immunological, immunohistochemical and molecular analyses of MS tissue suggest that the 
development of this disease is driven by a Th1+Th17+ type of inflammatory response, in concert with 
an autoantibody reaction directed against defined CNS myelin and possibly neuronal components.  
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Studies both in MS patients and EAE animals have shown evidences of thymic engagement during 
disease development (Duszczyszyn et al., 2010; Hara et al., 1986). Herein in a chronic EAE model we 
also showed that the thymus is playing a crucial role in the sense that, among other characteristics, 
there is thymic atrophy, as assessed by a decrease in total thymus weight, normalized for total body 
weight, and total number of cells. 
Using the CD4/CD8 markers we studied the alterations in thymic populations induced by EAE, at the 
onset and chronic phases of disease. Of interest, we found a decrease in the percentage of DP cells, 
and an increase in the percentages of CD4 and CD8 single positive cells, at the onset phase. The 
proportions of these populations were then restored to the levels of non-induced animals at the chronic 
phase of disease. Using WT animals induced with recombinant MOG instead of MOG35-55, Litwak and 
colleagues (2013) observed similar alterations in the DP and single positive thymocytes percentages. 
These two models differ in the sense that MOG35-55 induced EAE is independent of B cells, and the 
induction with recombinant MOG requires the endocytosis and presentation of the antigen by B cells. In 
this study, they observed a decrease in DP and an increase in single positive percentages in a more 
active phase of disease (day 18 post-disease induction), but at the chronic phase of disease they only 
observed a partial recovery of the DP population (recovery from approximately 20% to 55% by day 45). 
Since they don’t present the results from non-induced animals, it is not possible to evaluate if this 
recovery was sufficient to re-establish the normal populations’ percentages. In our case we saw a 
recovery, to non-induced animals’ levels, of the proportions between the different populations in EAE 
animals already at day 23 after disease induction. Interestingly, and contrary to our results, they also 
observed a recovery in DP cell number (Litwak et al., 2013).  
To our knowledge, this was the only other study that evaluated the thymus populations, in a chronic 
model of EAE induced in WT animals, at different timepoints of disease, namely at the peak and chronic 
phases. Previous studies focused on a single timepoint, to compare differences between genotypes 
(Gran et al., 2010) or treatments (Siatskas et al., 2012), or on Treg cells function (Chen et al., 2009; 
Zelenay et al., 2010). 
Very different animal models have shown to present thymic atrophy and alterations in thymocyte 
populations. Namely, an animal model of nutritional deprivation presented a decrease in the absolute 
numbers of all four thymocyte populations (Howard et al., 1999), similarly to what happens in our 
model. Besides, in this model, the greatest effect was also observed in the DP population, with a 
decrease in the relative proportion of this population. As for the relative proportions of the other 
thymocyte populations, they reported an increase in CD4 single positive cells, similarly to what we have, 
 52 
 
but the relative proportions of the DN and CD8 single positive populations were not altered in their 
model (Howard et al., 1999). Also, after herbicide exposure, animals presented a decrease in thymus 
weight:body weight ratio and in DP thymocytes number (de la Rosa et al., 2005). In both studies, the 
elevated serum corticosterone levels resulting from the stressful situation, were suggested as a possible 
cause for the thymic alterations. For that reason we also quantified corticosterone levels in our animal 
model. 
4.1.1 Influence of the hypothalamic-pituitary-adrenal (HPA) axis in thymic alterations in the EAE 
animal model induced in WT 
The activation of the HPA axis, during stressful stimuli or pathological conditions, can induce thymic 
alterations. This stress-induced thymic atrophy is characterized mainly by acute loss of cortical DP 
thymocytes, which is the most represented thymic population. Unlike age-induced thymic atrophy, 
which cannot be reverted, stress-induced atrophy is usually followed by spontaneous recovery, after the 
stressor has been removed (Gruver & Sempowski, 2008).  
To evaluate if the thymic atrophy observed in WT MOG35-55 induced EAE was caused by the increase in 
corticosterone levels we quantified it in the serum of the animals. Although the corticosterone levels 
were slightly increased at the onset phase of EAE, these levels were not significantly different from the 
levels neither of the non-induced animals nor from the ones of EAE animals at the chronic phase of 
disease. Still, we need to increase the number of animals to confirm these results. Also the serum used 
for corticosterone quantification was collected at the day of the sacrifice, when the animals were 
exposed to increased levels of stress. So it would also be important to quantify corticosterone basal 
levels, in serum collected at the nadir and zenith phases. 
It has previously been shown that both lymphotoxin and estrogen are able to induce thymic atrophy, in 
adrenalectomized animals, i.e., without the influence of elevated levels of glucocorticoids (Hirahara et 
al., 1994). Taking this into consideration, and to better understand the role of the HPA axis in the 
MOG35-55-induced chronic model of EAE, it would be interesting to induce the EAE in the animals, and 
then treat them with metyrapone or mifepristone, which, respectively, block the corticosterone synthesis 
and act as steroid receptor antagonist, to assess if thymic alterations previously observed in this model 
are reverted or maintained. Moreover, in a model of acute endotoxin-induced thymic atrophy, the 
thymus was found to actively respond to stress by up-regulating cytokine and chemokine gene 
expression, and down-regulating the expression of genes involved in lymphocyte activation and 
thymocyte differentiation, which could indicate that the intrathymic gene alterations may also contribute 
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to thymus atrophy (Billard et al., 2011). So it would also be relevant to study the expression levels of 
genes involved in the pro-inflammatory response and in thymocyte differentiation, in the thymus in our 
EAE model. 
4.1.2 Histological alterations in the thymus 
In a model of EAE induced in Lewis rats, after immunization with homogenized brain tissue, it was 
possible to observe marked atrophy, and the histological examination revealed severe degeneration of T 
cells, and infiltration of the thymus by macrophages showing phagocytic activity (Hara et al., 1986). To 
assess if the alterations in the thymocytes populations would translate into morphological alterations in 
the thymus, we stained paraffin sections of thymus with HE. We observed a loss of cortico-medullary 
distinction in EAE animals, during the onset phase of disease, in animals with higher clinical scores 
(clinical score=3), but not in earlier stages of disease development (score=1). Also, in animals with 
higher clinical scores, there was an almost complete abrogation of the medulla, resultant from the great 
decrease in the DP cell population, which is the most abundant population in the thymic medulla. 
Considering that the proportion of this cell population was restored in the chronic phase of disease, to 
the levels of non-induced animals, it would be important to evaluate the thymic morphology also during 
this phase of the disease. 
Also, to further explore the morphological alterations that occur in the thymus during EAE development, 
namely regarding the thymic epithelial cells, it would be important to assess the cortical/medullary 
ratio, after double staining  for cytokeratin (CK)5 and CK8, which are expressed in medullary and 
cortical epithelial cells, respectively. 
4.2 Role of LCN2 in the pathophysiology of EAE 
4.2.1 Disease development in LCN2-null mice 
The role of LCN2 in different disease models is contradictory, with some authors proposing a beneficial 
and others detrimental roles of LCN2. Regarding the development of immune complex-mediated 
inflammatory diseases, such as arthritis and systemic lupus erythromatous, LCN2 was found to play a 
protective role (Shashidharamurthy et al., 2013). On the other hand, using a model of spinal cord 
injury, LCN2 played a detrimental role, by contributing to neuronal and astrocyte loss, pro-inflammatory 
cytokine expression, and immune cell infiltration at the lesion site  (Rathore et al., 2011). Specifically 
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for the EAE model, previous works where EAE was induced in LCN2-null mice also present 
contradictory results. Berard and coworkers (2012) have reported that LCN2-null mice presented a 
more severe disease, when compared to WT animals, but, on the other hand, Nam and colleagues 
(2014) observed a reduced severity and delayed disease course in LCN2-null mice. Our results point to 
a different direction, indicating that LCN2 deficiency does not influence the clinical score of the animals. 
Possible explanations for the differences between all these results will be discussed next. 
When it comes to the experimental procedure to induce EAE, our protocol is very similar to the 
protocols used by the two groups mentioned, except for the day of the second PTX injection, which was 
at day 1 in our case and at day 2 in both the other cases, and for the PTX concentration – we 
administered 217ng of PTX per animal, while the other studies have administered 200ng per animal 
(Nam et al., 2014) and 400ng per animal (Berard et al., 2012). A higher concentration of PTX 
exacerbates the disease course, which could explain the fact that our group and Berard’s (2012) had 
higher scores than Nam and colleagues (2014).  
Besides, we used older females (10-16 weeks of age) compared to the ones previously used (7-11 
weeks) (Berard et al., 2012; Nam et al., 2014). Age has been shown to alter the disease incidence and 
severity in EAE models, namely it has been shown that EAE severity decreases with age, in a EAE 
model induced in female rats using spinal cord homogenate at 3, 8 and 26 months of age (Djikic et al., 
2015). Previously, male C57BL/6 mice with 8 months of age, induced with MOG35-55, had presented a 
worst disease phenotype compared with 6-8 weeks old mice (Matejuk et al., 2005).  
It is important to notice that in the study by Berard and coworkers (2012) their conclusions about the 
increased severity in LCN2-null mice is mainly based in results obtained from animals that developed a 
relapse-remitting  disease course, which is not the case of our model. Specifically for the animals that 
developed a chronic disease course, they also could not find differences between the mean day of onset 
disease nor between the mean clinical score at disease peak. They could only find differences between 
genotypes at the end stage of disease (day 28), when the LCN2-null mice presented a more severe 
mean clinical score. Our experimental endpoints were at days 16 and 23, so we cannot predict if we 
would have differences between genotypes at day 28. Also their scoring scale is different than the one 
used by us – our score of 3 corresponds to their 4 (hind limb paralysis).  
In the study by Nam and colleagues (2014), the score progression curve of LCN2-null mice was inferior 
to the WT mice along the experiment, indicating a less severe phenotype in the null mice. Also, the 
mean day of disease onset and the maximum score was reduced in LCN2-null mice when compared to 
WT mice. In their study only 1 LCN2-null mouse, in a total of 12, developed complete hind limb 
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paralysis, unlike the WT animals, in which 9 out of 12 animals became paralyzed, during the 35 days of 
experiment. In our case, and referring only to the animals sacrificed at the chronic phase, only 1/15 for 
the WT animals and 1/11 for the LCN2-null mice did not became paralyzed, which indicates identical 
severity of the disease in both of our groups. However, we did observed that 5/11 LCN2-null mice 
recovered the movement in the hind limbs after complete paralysis, against only 3/15 WT mice, which 
also points towards a more detrimental role of LCN2 in the context of EAE. 
4.2.2 Thymus alterations and the HPA axis in LCN2-null mice 
The LCN2-null mice presented the same alterations in thymic populations as observed in WT animals, 
namely, a decrease in all thymocyte populations, at the onset and chronic phases of disease, a 
decrease of DP cells percentage and an increase in CD4+ and CD8+ single positive cells, at the onset 
phase, and a reestablishment of these percentages at the chronic phase. But, unlike EAE WT animals, 
which did not present elevated levels of corticosterone, the LCN2-null mice at the onset phase of EAE 
presented increased levels of this hormone, as compared with the non-induced animals and the LCN2-
null mice at the chronic phase of disease. These results are consistent with the ones obtained in a 
MBP-induced EAE model, in Lewis rats (MacPhee et al., 1989). This model presented elevated levels of 
corticosterone just before the onset of paralysis, and the peak of corticosterone was coincident with the 
maximal clinical score. Besides that, the spontaneous recovery of the animals, from clinical symptoms, 
occurred when the corticosterone levels were still elevated, which indicated that elevated levels of 
corticosterone could be involved in EAE recovery. This hypothesis was further supported by the fact that 
bilateral adrenalectomy before disease induction resulted in a rapid disease development and in 100% 
of mortality rate. Moreover, the administration of corticosterone to these animals was able to revert this 
phenotype. It could be that in the LCN2-null mice, after EAE induction, the initial inflammatory response 
taking place in the CNS contributes to elevate corticosterone levels, which in turn will impair thymic 
function, preventing the differentiation of new activated cells, and thus act as a protection mechanism. 
As already discussed previously, we need to increase the number of animals in this analysis, to verify if 
this also happens in WT animals. The decrease in inflammatory infiltrates in the cerebellum of the 
LCN2-null animals at the chronic phase of disease is consistent with this protective role of 
corticosterone. 
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4.2.3 Inflammation in the cerebellum 
Most EAE studies are mainly focused in the alterations that occur in the spinal cord, and only few 
present data regarding the cerebellum. In our study we wanted to evaluate if the deficiency in LCN2, 
which is a protein involved in the acute phase response to inflammatory stimuli, would influence the 
inflammatory response to EAE, in the cerebellum. The importance of Th1 and Th17 cells in EAE 
development has long been recognized, and indeed we observed an increase in the expression levels of 
cytokines involved in the Th1 and Th17 responses, namely of Ifn-gamma, Il12a and Il17a, in both the 
WT and LCN2-null mice, during the onset phase of disease. During the chronic phase, the expression 
levels of these cytokines decreased. Besides this, the LCN2-null mice presented a less inflammatory 
profile in the cerebellum, characterized by decreased expression levels of Ifn-gamma, Il12a and Il17a 
when compared with the WT animals. Nevertheless, differences between genotypes were only 
statistically significant for the expression levels of Ifn-gamma, during the onset phase of disease. Nam 
and colleagues (2014) showed similar results for the expression levels of these cytokines in the spinal 
cord of WT and LCN2-null mice, at day 17 after EAE induction. They also mention that at the chronic 
phase of disease (day 30 after EAE induction), the expression levels of Il12 was similar in LCN2-null 
and WT mice, but they do not show if the expression levels were increased or decreased compared with 
the levels of day 17. Contrarily, Berard and co-workers (2012) had shown an increase in the expression 
of Ifn-gamma in LCN2-null EAE mice, compared with WT animals, between days 28-32 after EAE 
induction. However, they compared LCN2-null mice with a chronic disease course with WT animals that 
developed a relapse-remitting disease, and they had previously shown that WT animals with a chronic 
disease presented increased expression levels of this cytokine compared with WTs with a relapse-
remitting disease (Berard et al., 2010). As for the expression levels of Il4, a cytokine produced by Th2 
cells, they were not altered by EAE induction, in both genotypes. 
To evaluate the percentage of area occupied by inflammatory infiltrates, in the cerebellum, 
representative sections of the entire cerebellum of EAE animals were stained with luxol fast blue. Both 
WT and LCN2-null mice presented a decrease in the percentage of lesioned areas in the chronic phase 
of EAE, compared with the onset phase, similarly to the pattern observed for cytokine gene expression, 
and again the LCN2-null mice presented a lower percentage of lesion areas, in the onset phase, 
compared with WT animals, although not statistically significant. Nam and co-workers (2014) studied 
the presence of inflammatory infiltrates and demyelination not in the cerebellum, but in the spinal cord, 
and have shown that LCN2-null EAE mice presented less inflammatory infiltrates and less 
demyelination in the spinal cord, compared with WT EAE animals. In our case, the LCN2-null mice 
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seem to present less inflammatory infiltrates, but the difference is not statistically significant. In our 
study, the range of clinical scores at the onset of disease was elevated, ranging from 1.5 to 4, which 
increased the variability inside the groups at this phase of the disease. Also, they used a qualitative 
measurement to evaluate the histological score (scale from 0 to 4), and we used a quantitative 
measure, which involved the delimitation of all lesioned areas per section, in a total of 7 sections per 
animal, and the normalization for the total white matter. Berard and colleagues (2012) also evaluated 
lesioned areas in the spinal cord of LCN2-null and WT mice induced with EAE, and found an increase in 
the total lesioned area per section in the LCN2-null mice when compared with the WT animals. As 
already mentioned for the gene expression, in this case they also compared LCN2-null animals with a 
chronic disease course, and WT animals with a relapse-remitting course, while they had previously 
shown that WT animals with chronic EAE presented an increase in total lesion area, when compared to 
WT animals with relapse-remitting EAE (Berard et al., 2010). So, the differences found between LCN2-
null mice and WT animals could be due to differences in the disease course, and not differences 
between genotypes. In another study, the total lesion frequency was evaluated in the cerebellum of 
female C57BL/6 animals induced with MOG35-55, using the HE staining instead of the luxol fast blue. 
Several timepoints were assessed, during a period of 50 days, and, contrarily to our results, they 
observed that the number of inflammatory infiltrates was greater at day 16 after EAE induction, and 
persisted to a similar extent until the end of the experiment. In this study the results were presented as 
the sum of the total number of meningeal and parenchymal infiltrates (Kuerten et al., 2007), while in 
our case we measured the total area of inflammatory infiltrates, and normalized the results for the total 
white matter area. Interestingly, we found a high correlation between the percentage of lesioned area, 
in the cerebellum, and the clinical score of the animals, while Kuerten and co-workers (2007) did not 
found a correlation between the clinical score and lesion frequency or lesion size, both in the brain and 
in the spinal cord of MOG35-55-induced animals. 
To further confirm that the delimited lesion areas in the luxol fast blue staining correspond to 
demyelination areas, we could stain a consecutive section with a myelin marker, like fluoromyelin or an 
antibody specific for MOG, and check if the areas overlap. Using these stainings, we could also quantify 
the percentage of demyelination in the cerebellum. It would also be interesting to stain cerebellum 
sections with OPCs markers, such as NG2 or platelet-derived growth factor receptor (PDGFR)α, and 
also mature oligodendrocyte markers, like 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase), at 
both timepoints, to assess if these cells are present near lesion sites, and if they could be involved in 
the remyelination process. 
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4.2.4 Astrogliosis in the cerebellum 
Previously, it was shown that in the context of a relapse-remitting model of EAE, astrocytes were the 
only cells producing LCN2, except for infiltrating neutrophils (Marques et al., 2012), so, in order to 
evaluate the influence of LCN2 in astrocyte morphology and activation, in the cerebellum of EAE mice 
MOG35-55-induced, we stained cerebellum slices from LCN2-null mice and WT littermates with GFAP, at 
the onset and chronic phases of EAE. LCN2-null mice and WT littermates non-induced were used as 
controls. Posteriorly, fluorescence images were taken, from the cerebellar white matter, and were used 
to quantify the total GFAP+ area with the Fiji software.  
Both genotypes presented an elevation in total GFAP+ area, at the onset and chronic phases of disease, 
when compared to non-induced animals. Previously, the GFAP fluorescence intensity was also 
quantified, in the spinal cord of LCN2-null and WT mice induced with EAE (Nam et al., 2014). They 
found a decreased activation of astrocytes in LCN2-null mice compared to WT animals, as assessed by 
a decrease in the fluorescence intensity. In addition, other studies using LCN2-null mice have shown a 
decreased GFAP expression, compared to WT animals, after intracerebroventricular injection with LPS 
(to induce inflammation) or cortical stab wounding (to induce injury) (Lee et al., 2011). In our study we 
could not find differences between genotypes, but we only have 3 animals per group, so it would be 
valuable to increase the number of animals. Regarding the expression levels of the Gfap gene, they 
were only elevated during the onset phase of disease, in both genotypes. In this case, for gene 
expression evaluation, we used the entire cerebellum, including white and grey matter, while the 
photographs to evaluate the GFAP+ area were only taken in the cerebellar white matter. Also, it is 
possible that the elevated levels of GFAP protein, resultant from the increase in gene expression during 
the onset phase, were not cleared by the time the animals reached the chronic phase.  
Besides studying the astrocytes, it would also be interesting to evaluate microglial activation in the 
cerebellum of LCN2-null mice and WT animals, induced with EAE, at both the onset and chronic phases 
of disease, and if possible microglial morphology. 
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5. CONCLUDING REMARKS  
The role of the thymus in EAE development is extremely important, not only because CD4+ and CD8+ T 
cells that could become auto-reactive are differentiated in this organ, but also because it is responsible 
for the production of Treg cells, which try to control the activity of auto-reactive cells. However, few 
studies have been made to characterize the morphological and functional alterations that occur in the 
thymus after EAE induction. Even though we have assessed thymocyte populations at two timepoints 
during disease development, namely the peak of activity of disease and a chronic phase, some 
questions still remain. Are the thymic populations already altered before the appearance of the first 
symptoms? Are the corticosterone levels solely responsible for thymic atrophy, in the context of the 
chronic EAE model? What other factors could also be contributing to thymic atrophy? Does LCN2 
influence the production of Treg cells? 
Still, the flow cytometry results showing alterations in the proportion of thymic populations, during the 
onset of EAE, but not during the chronic phase, suggests a role of the thymus in disease establishment, 
and the better we understand that role, the better we will be able to modulate thymic activity and 
prevent auto-immune diseases. 
Regarding the role of LCN2 in MS disease, so far, two other studies have tried to unravel the role of 
LCN2 in MS pathogenesis, by using the LCN2-null animals induced with EAE, but these studies have 
shown contradictory results. The contradictions are mainly related with the clinical outcome of the 
disease, which is evaluated using a scoring scale highly dependent on the observer. So unless other 
types of scales are developed, for the evaluation of disease development on EAE, or unless each scale 
number has a specific and distinct characteristic, facilitating its usability, the comparisons between 
studies will continue to present difficulties. In addition, the microbiological environment in which the 
animals live in, i.e., the microbiological status of the animal facilities, is known to affect the 
immunological state of the animals. Considering that we are studying a protein involved in the acute 
phase response to inflammatory stimuli, in the context of an auto-immune disease, we should always 
take into consideration factors that can alter the immunological response in the animals. Apart from 
this, most EAE studies are performed in female mice, and little is known about the possible influence of 
the estrous cycle phase in disease development. Recently it was published that EAE induction disrupted 
the estrous cycle in female SJL/J mice, but is it possible that the appearance of the first symptoms 
could be influenced by the phase of the cycle at the time of disease induction?  
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Globally, our results show a similar pattern of response both in the CNS, in the cerebellum, and in the 
periphery, specifically in the thymus, characterized by increased alterations during the peak of activity of 
disease, and a re-establishment to normal levels at the chronic phase. In more detail, in the thymus, 
during the onset phase of disease, the percentage of DP cells is decreased, and the percentages of 
CD4 and CD8 single positive cells are increased, when compared with non-induced animals. 
Remarkably, although the total number of cells from each of the thymic populations remained 
decreased during the chronic phase, the proportions between the different populations were restored. It 
remains uncertain if the morphology of the thymus is also re-established. 
In what concerns the LCN2, and its role in EAE, our results suggest a less inflammatory profile in these 
animals, characterized by the presence of less inflammatory infiltrates and decreased expression of pro-
inflammatory cytokines in the cerebellum. This goes according to previously published data, in which 
LCN2 was found to play a protective role during EAE development. Still, in our case, the decreased 
inflammatory profile did not translate into an improvement in the clinical score. So, it would be 
interesting to also evaluate the spinal cord of our animals, to compare with previous results and try to 
understand what are the factors that could be contributing for the lack of improvement in the clinical 
score of our LCN2-null mice induced with EAE. 
Although previous work form our group has shown elevated levels of LCN2 in the CSF of MS patients, 
comparing with healthy-controls, more studies with MS patients should be done to assess if LCN2 could 
be used as a disease marker, if its’ levels were able to distinguish MS from other inflammatory diseases 
of the CNS, or as a predictor of evolution from CIS to definite MS. Also, longitudinal studies could 
evaluate the value of LCN2 as a predictive factor of disease progression.  
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ANNEX I – DNA SEQUENCES OF THE PRIMERS USED IN QRT-PCR 
Mouse 
cDNAs 
Primer sequences 
GenBankTM accession 
number 
Annealing 
temperature/ºC 
Hprt 
Forward: 5’ GCT GGT GAA AAG GAC CTC T 3’ 
NM_013556.2 59 
Reverse: 5’ CAC AGG ACT AGA ACA CCT GC 3’ 
Il-17a 
Forward: 5’ GGA CTC TCC ACC GCA ATG AA 3’ 
NM_010552.3 59 
Reverse: 5’ CAT GTG GTG GTC CAG CTT TC 3’ 
Il-12a  
Forward: 5’ GTG TCT TAG CCA GTC CCG AA 3’ 
NM_008351.3 59 
Reverse: 5’ TTC AAG TCC TCA TAG ATG CTA CCA A 3’ 
Il-4  
Forward: 5’ GTC ACA GGA GAA GGG ACG CCA T 3’ 
NM_021283.2 59 
Reverse: 5’ AGC CCT ACA GAC GAG CTC ACT C 3’ 
Inf-γ  Forward: 5’ CAA CAG CAA GGC GAA AAA GG 3’ NM_008337.3 59 
Reverse: 5’ GGA CCA CTC GGA TGA GCT CA 3’ 
Gfap 
Forward: 5’ AAA CCG CAT CAC CAT TCC TG 3’ 
XR_388347.2 59 
Reverse: 5’ TCT GGT GAG CCT GTA TTG GG 3’ 
 
 
